

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6186934

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSET TRANSFER AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
ELAN PHARMA INTERNATIONAL LIMITED	08/02/2011
RECEIVING PARTY DATA	
Name:	EDT PHARMA HOLDINGS LIMITED
Street Address:	TREASURY BUILDING
Internal Address:	GRAND CANAL STREET LOWER
City:	DUBLIN 2
State/Country:	IRELAND
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16550239
Application Number:	16894247
CORRESPONDENCE DATA	
Fax Number:	(412)454-5060
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	412-454-5000
Email:	docketingpgh@troutman.com
Correspondent Name:	TROUTMAN PEPPER HAMILTON SANDERS LLP
Address Line 1:	UNION TRUST BUILDING
Address Line 2:	501 GRANT STREET, SUITE 300
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15219-4429
ATTORNEY DOCKET NUMBER:	148428.01071
NAME OF SUBMITTER:	MICHAEL VERTULLO
SIGNATURE:	/Michael Vertullo/
DATE SIGNED:	07/06/2020
Total Attachments: 82	
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page1.tif	
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page2.tif	
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page3.tif	
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page4.tif	

source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page53.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page54.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page55.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page56.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page57.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page58.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page59.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page60.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page61.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page62.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page63.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page64.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page65.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page66.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page67.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page68.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page69.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page70.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page71.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page72.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page73.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page74.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page75.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page76.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page77.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page78.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page79.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page80.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page81.tif
source=Elan_to_EDT_Pharma_Holdings_148428_1071_1081#page82.tif

Step 6
Trading Assets Agreement (EPIL to EDT Pharma Holdings)

Dated 2 August 2011

ELAN PHARMA INTERNATIONAL LIMITED
(Vendor)

and

EDT PHARMA HOLDINGS LIMITED
(Purchaser)

ASSET TRANSFER AGREEMENT

for the purchase of the trading assets relating to the Drug Delivery Business of
ELAN PHARMA INTERNATIONAL LIMITED

A & L GOODBODY

THIS ASSET TRANSFER AGREEMENT is dated 2 August 2011 and made between

- (1) **ELAN PHARMA INTERNATIONAL LIMITED** (registered no. 222276) having its registered office at Monksland, Athlone, Co. Westmeath (**Vendor**); and
- (2) **EDT PHARMA HOLDINGS LIMITED** a company incorporated in Ireland (Registered No. 448848) whose registered office is at Treasury Building, Grand Canal Street Lower, Dublin 2 (**Purchaser**).

RECITALS:

- A. The Vendor is carrying on a trade of the purchase, development and exploitation of certain intellectual property rights and is the owner of certain trading assets (including intellectual property rights) relating to the EDT Business.
- B. Under the Business Transfer Agreement, the Purchaser has acquired the manufacturing business forming part of the EDT Business including the employees engaged in connection therewith.
- C. The Vendor has agreed to sell and the Purchaser has agreed to purchase the Trading Assets upon the terms and subject to the conditions of this Agreement and will use these trading assets in the course of its manufacturing business.
- D. As set out in Section 7.1(k) of the Merger Agreement, the Purchaser will, for so long as it is a member of the Elan Tax Group, carry on its business in the same manner as the Vendor and will carry the Trading Assets as trading stock for tax purposes. The Trading Assets under this Agreement should not include any assets relating to the EDT Business other than assets which were held as trading stock by the Vendor.

IT IS HEREBY AGREED as follows:

1. PRELIMINARY

1.1. **Definitions:** In this Agreement and in the Schedules unless the context otherwise requires:

1963 Act means the Companies Act, 1963;

1990 Act means the Companies Act, 1990;

Authorisations means those authorisations, licences and permits necessary for the conduct of the EDT Business which are in the name of the Purchaser;

Business Contracts means all contracts, agreements, arrangements and understandings of every kind with customers of the EDT Business and other contracts relating to the EDT Business, which form part of the Trading Assets;

Business Day means any day on which banks are generally open for business in Dublin excluding Saturdays and Sundays;

Business Transfer Agreement means the agreement dated 26 July 2011 pursuant to which the Purchaser has acquired the Manufacturing Business from Elan Science Five Limited;

Completion means completion of the sale and purchase of the Trading Assets pursuant to this Agreement;

Conditions means the pre-conditions to closing listed in clause 3.2;

Confidential Information means any and all information received or obtained as a result of (i) the operation of the EDT Business and/or (ii) entering into or performing, or supplied by or on behalf of a party in the negotiations leading to, this Agreement and which in each case relates to:

- (a) the EDT Business;

- (b) the Manufacturing Business;
- (c) the provisions of this Agreement;
- (d) the negotiations relating to this Agreement;
- (e) the subject matter of this Agreement; or
- (f) the Purchaser or any subsidiary or holding company of the Purchaser;

EDT Business means the suite of activities including: research, development, drug optimization and delivery utilizing Elan's proprietary drug delivery technologies (including its NanoCrystal® technology for poorly water-soluble compounds, and its range of oral controlled release delivery technologies comprising extended, delayed and pulsatile release); drug scale up capabilities including formulation development, analytical development, clinical trial manufacturing and scale-up and product registration support; performing such research and development services for third parties; licensing or otherwise permitting the practice and use by third parties of such Elan proprietary drug delivery technologies or products incorporating such drug delivery technologies; and commercial manufacturing of pharmaceutical dosage forms both for products incorporating Elan proprietary technologies, the Fill/Finish Business and all contract manufacturing carried on by the Vendor;

Effective Date means the date of this Agreement;

Employees means those employees of the Vendor employed in connection with the Trading Assets;

Elan Tax Group means Elan Corporation plc and all of its wholly owned direct and indirect subsidiaries resident for tax purposes in Ireland;

Encumbrance includes, without limitation, any interest or equity of any person (including any right to acquire any option) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest (including any created by law), title retention or other security agreement or arrangement or a rental, hire purchase, credit sale or other agreement for payment on deferred terms;

Excluded Assets means those assets of the Vendor set out in Schedule 1 which are not being sold hereunder;

Fill/Finish Business means the fill/finish business carried on by the Vendor at Building 17 on the EDT Business campus at Monkstown Industrial estate, Athlone, Co. Westmeath;

Information means all customer and supplier records and correspondence (including, in each case, the full name and the address and addresses for delivery or collection or for provision of services) relating to the EDT Business, all books of account relating to the EDT Business and other records of the EDT Business for the six years prior to Completion, all deeds and documents evidencing title to the Trading Assets (duly stamped where appropriate), all sales and technical literature and all other documents, computer records and programs relating to or required for the due and efficient carrying on of the EDT Business and all files and other relevant information relating to the Employees;

Intellectual Property means any and all rights pertaining to inventions, discoveries, trade secrets, confidential business information, financial, marketing and business data, concepts, ideas and improvements to existing technology (in each case whether or not written down or otherwise converted to tangible form), patents, patent applications, patent disclosures, designs, trade marks, service marks, trade names, logos, rights in any domain names, algorithms, database rights, goodwill, copyright(s), moral rights, know-how, reputation, modes, get-up, computer programs and analogous property, plans, models, and all other forms of industrial or intellectual property (in each case in any part of the world and whether or not registered or registerable and to the fullest extent thereof and for the full period therefor and all extensions and renewals thereof), all applications for registration of the foregoing and all rights and interest, present and future thereto and therein;

Intellectual Property Rights means such Intellectual Property used exclusively in connection with the EDT Business and such other Intellectual Property as are included in the Trading Assets;

Ireland means Ireland excluding Northern Ireland and Irish will be construed accordingly;

Licence User Agreement means an agreement entered into on today's date by the Vendor and the Purchaser pursuant to which the Vendor agrees to sub-licence the Authorisations to the Purchaser;

Loan Note means the loan note to be issued by the Purchaser in the name of the Vendor in the amount of _____ on Completion pursuant to clause 3.4;

Manufacturing and Supply Agreement means the agreement entered into by Elan Science Five Limited (ES5) and the Vendor on 28 July 2011 whereby ES5 has agreed to manufacture and supply to the Vendor certain products and the Vendor has agreed to purchase the products upon the terms set out in the agreement;

Manufacturing Business means all the capital assets, manufacturing assets, real property, fixtures and fittings and all other assets owned by the Vendor, other than the Excluded Assets including the Vendor's obligations under the Manufacturing and Supply Agreement, which are to be acquired by the Purchaser pursuant to the Business Transfer Agreement;

Merger Agreement means the business combination agreement and plan of merger entered into by Elan Corporation, plc, Antler Science Two Limited, Elan Science Four Limited, EDT Pharma Holdings Limited, EDT US Holdco Inc., Antler Acquisition Corp. and Alkermes, Inc. on 9 May 2011;

Patents means the patents listed at Schedule 2 to this Agreement;

Taxation and Tax means all forms of taxation, duties, imposts and levies whether of Ireland or elsewhere, including (but without limitation) income tax, corporation tax, corporation profits tax, advance corporation tax, capital gains tax, capital acquisitions tax, residential property tax, wealth tax, value added tax, customs and other import and export duties, excise duties, vehicle registration tax, stamp duty, capital duty, social insurance, social welfare or other similar contributions and other amounts corresponding thereto whether payable in Ireland or elsewhere, and any costs, interest, surcharge, penalty or fine relating to the same and any penalties chargeable for non-compliance with any statutory provisions or regulations in connection therewith and the word **taxation** shall be construed accordingly;

TCA means the Taxes Consolidation Act, 1997;

Termination Letter means a letter dated the date of this Agreement between the Vendor and the Purchaser pursuant to which the Manufacturing and Supply Agreement is to be terminated;

Trading Assets means the assets listed in Clause 2.1 including all the Intellectual Property owned by the Vendor in respect of or related to the EDT Business, other than for the avoidance of doubt the Excluded Assets, all of which are to be acquired by or novated in favour of the Purchaser pursuant to this Agreement; and

VAT means value added tax within the meaning of the Value-Added Tax Consolidation Act 2010.

- 1.2. The Schedules referred to in this Agreement form an integral part of this Agreement, and references to this Agreement include reference to them.
- 1.3. Headings are inserted for convenience only and do not affect the construction of this Agreement.
- 1.4. All references in this Agreement to costs, charges or expenses include any value added tax or similar tax charged or chargeable on them.
- 1.5. Unless expressly stated in this Agreement or the context otherwise requires, in this Agreement:
 - 1.5.1. references to persons are deemed to include references to natural persons, firms, partnerships, companies, corporations, associations, bodies corporate, trusts and investment funds (in each case whether or not having a separate legal personality) but references to individuals are deemed to be references to natural persons only;
 - 1.5.2. words importing the singular include the plural and vice versa and words importing the masculine include references to the feminine and neuter and vice versa;
 - 1.5.3. reference to writing or similar expressions includes transmission by facsimile or electronic means;

- 1.5.4. a word or phrase the definition of which is contained or referred to in section 2 of the 1963 Act has the meaning attributed to it by that definition;
- 1.5.5. references to Acts, statutory instruments and other legislation are to legislation operative in Ireland and to such legislation, modified, consolidated, amended or re-enacted (whether before or after the date of this Agreement) and any subordinate legislation made under that legislation;
- 1.5.6. reference to any Irish legal term, concept, legislation or regulation (including, those for any action, remedy, method of judicial proceeding, document, statute, court official, governmental authority or agency) or any accounting term or concept, in respect of any jurisdiction other than Ireland will be construed as a reference to the term or concept which most nearly corresponds to it in that jurisdiction;
- 1.5.7. reference to this Agreement includes this Agreement as amended or supplemented from time to time; and
- 1.5.8. "including" and "includes" mean including or includes without limiting the generality of the foregoing.

2. SALE OF ASSETS

- 2.1. **Sale and Purchase:** Subject to the terms of this Agreement, the Vendor shall sell as legal and beneficial owner and the Purchaser shall purchase in reliance on the provisions of this Agreement free from all Encumbrances and together with all rights now or hereafter attaching thereto, the Trading Assets including:
 - 2.1.1. the Patents;
 - 2.1.2. the Intellectual Property Rights
 - 2.1.3. subject to clause 4 the full benefit subject to the burden (so far as the same is capable of assignment) of the Business Contracts and all of the Vendor's pending contracts engagements and all orders in connection with the EDT Business;
 - 2.1.4. the Authorisations;
 - 2.1.5. any related goodwill of the EDT Business and to represent the Purchaser as carrying on the EDT Business in continuation of that carried on by the Vendor and in succession thereto;
 - 2.1.6. the Information; and
 - 2.1.7. all other property in connection with the Intellectual Property Rights except the Excluded Assets.
- 2.2. **Other Benefits:**
 - 2.2.1. If the Vendor receives any sums or benefits in respect of any of the Trading Assets it shall forthwith pay or cause to be paid (as the case may be) to the Purchaser as soon as practicable and in any event within ten Business Days of receipt thereof to a bank account to be nominated by the Purchaser if being recognised and agreed by the Vendor that, if the Purchaser so requires, the Purchaser shall continue to invoice any customers in respect of contracts current at Completion.
 - 2.2.2. The Vendor shall forthwith upon the execution hereof notify the interest of the Purchaser to the insurers of the Trading Assets and the EDT Business and keep in force its existing insurance policies in respect of the Trading Assets until 180 days after Completion.
- 2.3. **The Consideration:**

The consideration for the said sale shall be satisfied by the issue of the Loan Note in the name of the Vendor.
- 2.4. **Purchase of all the Trading Assets:** The Purchaser will not be obliged to complete the purchase of

any of the Trading Assets unless the purchase of all of the Trading Assets is completed simultaneously.

2.5. Value Added Tax (VAT):

- 2.5.1. The parties shall use their best endeavours to ensure that by virtue of the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 no VAT will be chargeable in respect of the sale and purchase of the Trading Assets hereby agreed to be made.
- 2.5.2. Notwithstanding Clause 2.5.1, the Purchaser shall not be liable to pay to the Vendor or to any other person any amount representing VAT in respect of the sale of the Trading Assets unless the Vendor demonstrates to the satisfaction of the Purchaser that the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 do not apply. For the avoidance of doubt, written confirmation from the Irish Revenue Commissioners on this point shall be treated as demonstration to the satisfaction of the Purchaser.
- 2.5.3. Subject to Clause 2.5.2, if VAT is properly chargeable in respect of the sale of the Trading Assets and the Vendor is accountable in respect of the payment of the VAT to the VAT authorities, the Vendor shall deliver to the Purchaser a VAT invoice prepared in a format which is in accordance with relevant VAT legislation. On receipt of this VAT invoice the Purchaser shall pay to the Vendor the amount of VAT properly arising in respect of the sale of the Trading Assets.
- 2.5.4. Notwithstanding Clause 2.5.2, if following the payment of any amount of VAT by the Purchaser to the Vendor in respect of the sale of the Trading Assets it is established that VAT was incorrectly chargeable, the Vendor shall pay to the Purchaser the amount of any VAT incorrectly charged. For the avoidance of doubt, only written confirmation from the Irish Revenue Commissioners shall be treated as establishing that VAT was incorrectly chargeable.
- 2.5.5. In the event that the Vendor will incur a clawback of VAT in relation to or arising from the sale, the parties hereby exercise a joint option to tax within the meaning of section 94(5) Value-Added Tax Consolidation Act 2010.

3. COMPLETION AND CONDITIONS

- 3.1. **Completion:** Subject to clause 3.2, Completion shall take place on the Effective Date at such address as the parties may agree.
- 3.2. **Closing Conditions:** Completion of this Agreement will take place conditionally upon:
- 3.2.1. the simultaneous completion of the Business Transfer Agreement; and
- 3.2.2. the Vendor having complied with its obligations under clause 5.
- 3.3. **Actions at Completion:** Upon Completion:
- 3.3.1. possession of the Trading Assets shall, as far as practical, be delivered to the Purchaser;
- 3.3.2. the Vendor shall procure that all other necessary parties (if any) execute and deliver to the Purchaser all such assurances and things as may be necessary to vest in the Purchaser good and marketable title to the Trading Assets (including deeds of assignment in relation to the Intellectual Property) including such evidence of corporate power and proper execution as the Purchaser may reasonably require;
- 3.3.3. the Vendor and the Purchaser shall execute and deliver the Termination Letter;
- 3.3.4. the Vendor and the Purchaser shall execute and deliver the Licence User Agreement;
- 3.3.5. the Vendor and the Purchaser shall comply with the terms of clause 5 (in relation to the Employees); and
- 3.3.6. the Vendor shall cause to be delivered to the Purchaser a tax clearance certificate pursuant to section 980 of the Taxes Consolidation Act 1997 (as amended) (CGT Clearance Certificate)

confirming that the Purchaser does not have to deduct any sum representing capital gains tax on payment of the consideration to the Vendor.

- 3.4. **Payments at Completion:** The Purchaser shall on Completion issue the Loan Note in the name of the Vendor less withholding tax if the CGT Clearance Certificate is not produced by the Vendor stating that tax should not be deducted from the consideration.

4. BUSINESS CONTRACTS

- 4.1. At Completion the Vendor will, at the option of the Purchaser, in respect of each Business Contract:-

- 4.1.1. assign (or procure the assignment of) the Business Contract in question to the Purchaser or its nominee(s); or
- 4.1.2. procure the novation of the Business Contract in question so that the Purchaser or its nominee(s) will become party to the relevant Business Contract in place of the Vendor

in each case on such terms as may be agreed to by the Purchaser.

- 4.2. Insofar as the consent of a third party is required to comply with the terms of clause 4.1, the Vendor shall use its best endeavours to procure such consent at its own cost and expense. Until such consent is received, the Vendor shall, following Completion, at the Purchaser's option either:-

- 4.2.1. unless contractually prevented from so doing, sub-contract the relevant Business Contract to the Purchaser on the same terms and for the same remuneration that applies to that Business Contract; or
- 4.2.2. act in connection with the Business Contract in all respects as the Purchaser may reasonably direct from time to time

so that (without prejudice to generality of the foregoing) the Purchaser will perform the obligations and liabilities arising under the Business Contract in question insofar as any such obligation or liability arises after Completion (provided that no such obligation or liability is in respect of any breach of the relevant Business Contract by the Vendor prior to Completion) and the full benefit of all contractual rights, benefits and claims thereunder whether arising before or after Completion shall vest in and be held on trust by the Vendor for the Purchaser absolutely.

- 4.3. To the extent that the Vendor is not lawfully able to hold the Business Contract in question on trust for the Purchaser, the parties shall make such other arrangements between themselves as the Purchaser may reasonably require to provide that (i) the benefit of the Business Contracts in question is received by the Purchaser, including the enforcement of all rights of the Vendor thereunder and (ii) the Purchaser will be responsible for carrying out the Vendor's obligations under such Business Contracts as set out above from Completion.
- 4.4. If any Business Contract is being novated then this Agreement does not act as a contract or agreement for the sale of any estate or interest in the Business Contracts nor does it operate to assign any of the Business Contracts. Instead the benefit of the Business Contracts will be novated to the Purchaser pursuant to the deed of novation which is to be entered into between the parties.

5. EMPLOYEES

- 5.1. **Safeguarding of Employees' Rights:** The Vendor shall discharge all of its obligations (if any) in relation to the Employees arising under or by virtue of the European Communities (Protection of Employees on Transfer of Undertakings) Regulations, 2003.
- 5.2. **Evidence and Information:** The Vendor shall both before and after Completion furnish to the Purchaser such evidence and information as the Purchaser may from time to time require in relation to the discharge by the Vendor of the Vendor's said obligations together with such other information as the Purchaser may from time to time require in relation to the intentions, proposals, obligations and actions of the Vendor in connection with contracts of employment, employment relationships or collective agreements and any other matters in connection therewith relating to any of the Employees.
- 5.3. **Other Obligations:** The Vendor shall perform and shall be fully liable and responsible for all obligations

and liabilities whatsoever pertaining to matters arising prior to Completion arising by virtue of or in connection with contracts of employment, employment relationships and/or collective agreements in existence at any time prior to Completion (whether discovered before or after Completion) including under any applicable statute and the Vendor hereby fully and effectually indemnifies and agrees to keep the Purchaser fully and effectually indemnified against all judgments, claims, decrees, prosecutions, orders, awards, damages, costs, liabilities and expenses howsoever arising (including costs, payments and expenses of any reasonable settlement entered into by the Purchaser with the prior consent of the Vendor, such consent not to be unreasonably withheld, delayed or conditioned) under or by virtue thereof. In the event that any claim, arising from circumstances prior to Completion, is made against the Purchaser, the Vendor shall furnish to the Purchaser such evidence and information as the Purchaser may require to defend those claims.

- 5.4. **Transfer of Employees:** The Vendor shall prior to Completion comply where appropriate with sections 9(2) and 20 of the Redundancy Payments Act, 1967 and shall facilitate the Purchaser in this regard so that continuity, where appropriate, is maintained.
- 5.5. The Vendor and the Purchaser shall not prior to the Effective Time unless otherwise required by law or with the prior agreement of Alkermes, Inc.
- 5.5.1. increase or offer, promise or agree to increase the remuneration (howsoever defined but including salary and any variable and/or incentive arrangements) or the severance arrangements in respect of any of the Employees;
- 5.5.2. increase or make offers of employment so as to increase the number of the Employees; or
- 5.5.3. replace or offer to redeploy any of the Employees.

6. MISCELLANEOUS PROVISIONS

6.1. Confidentiality

- 6.1.1. The Vendor undertakes with the Purchaser that it shall preserve the confidentiality of, and not directly or indirectly reveal, report, publish, disclose, transfer or use for its own or any other purposes Confidential Information except:
- (1) in the circumstances set out in clause 6.1.2;
 - (2) to the extent otherwise expressly permitted by this Agreement; or
 - (3) with the prior written consent of the Purchaser.
- 6.1.2. The Vendor is permitted to disclose Confidential Information:
- (1) where the Confidential Information, before it is furnished to the relevant Vendor, is in the public domain;
 - (2) where the Confidential Information, after it is furnished to the relevant Vendor, enters the public domain otherwise than as a result of: (i) a breach by the relevant Vendor of its obligations in this clause 6.1 or (ii) a breach by the person who disclosed that Confidential Information of a confidentiality obligation where the relevant Vendor is aware of such breach;
 - (3) if and to the extent that a Vendor discloses Confidential Information to any person:
 - (a) in compliance with any requirement of law;
 - (b) in response to a requirement of any securities exchange, regulatory or governmental authority or court having jurisdiction over the relevant Vendor; or
 - (c) in order to obtain Tax or other clearances or consents from the Revenue Commissioners or other relevant taxing or regulatory authorities,

provided that any such information disclosable pursuant to paragraphs (a), (b) or (c) may be disclosed only to the extent specifically required by law.

6.1.3. The restrictions contained in this clause 6.1 will continue to apply after Completion and will apply in relation to the existence and provisions of this Agreement and information relating to the Purchaser regardless of whether or not Completion occurs.

6.2. Severability

All the terms and provisions of this Agreement are distinct and severable, and if any term or provision is held or declared to be unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it will to that extent only be deemed not to form part of this Agreement, and the enforceability, legality and validity of the remainder of this Agreement will not in any event be affected. The parties shall then use all reasonable endeavours to agree a term or provision to replace the unenforceable, illegal or void term or provision which is legal and enforceable and which has an effect that is near as possible to the intended effect of the term or provision to be replaced.

6.3. Whole Agreement

This Agreement (together with any documents to be executed pursuant to the terms of this Agreement) supersedes all prior representations, arrangements, understandings and agreements, and sets out the entire, complete and exclusive agreement and understanding between the parties. The rights of the Purchaser under this Agreement are independent, cumulative and without prejudice to all other rights available to it whether as a matter of common law, statute, custom or otherwise.

6.4. Survival

The provisions of this Agreement which have not been performed at Completion will remain in full force and effect notwithstanding Completion.

6.5. Remedies Cumulative

The provisions of this Agreement and the rights and remedies of the parties are cumulative and are without prejudice and in addition to any rights or remedies which a party may have at law or in equity. The exercise by a party of any one right or remedy under this Agreement or at law or in equity will not (unless expressly otherwise provided in this Agreement or at law or in equity) operate so as to hinder or prevent the exercise by that party of any other right or remedy.

6.6. Waiver

Any liability to the Purchaser under this Agreement may be wholly or partially released, varied, compounded or compromised by the Purchaser in its absolute discretion as regards the Vendor or any other party without in any way prejudicing or affecting its rights against any other party under the same or a similar liability, whether joint and several or otherwise. A waiver by the Purchaser of any breach by any party of any of the terms, provisions or conditions of this Agreement, or the acquiescence of the Purchaser in any act (whether commission or omission) which but for such acquiescence would be a breach, will not constitute a general waiver of the term, provision or condition or of any subsequent act which is inconsistent with it.

6.7. Further Assurance

6.7.1. Without limiting the generality of the foregoing, to the extent that the Purchaser or the Vendor discover following Completion that:

6.7.2. any Trading Asset that was intended to be assigned and transferred pursuant to this Agreement was not assigned and transferred at Completion, the Vendor shall (and shall procure that any other necessary parties shall) execute and do all such documents, acts and things as may reasonably be required to assign and transfer to the Purchaser the legal and beneficial ownership in such Trading Asset; and/or

6.7.3. any asset that was not a Trading Asset intended to be transferred pursuant to this Agreement was assigned and transferred at Completion, the Purchaser shall (and shall procure that any other parties shall) execute and do all such documents, acts and things as may reasonably be

required to assign and transfer to the Vendor the legal and beneficial ownership in such asset.

6.8. Notices

Any notice or other communication to be given or served under this Agreement shall be in writing, addressed to the relevant party and expressed to be a notice or communication under this Agreement and, without prejudice to the validity of another method of service, may be delivered or sent by pre-paid post or facsimile addressed to the recipient at the address given above or to its fax number at that address.

6.9. Counterparts

This Agreement may be executed in any number of counterparts, and by the several parties to it on separate counterparts, each of which when so executed will constitute an original but all of which together will evidence the same agreement.

6.10. Governing Law and Jurisdiction

This Agreement and all relationships created by it will in all respects be governed by and construed in accordance with Irish law. The Irish courts will have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement or its performance.

6.11. Succession and Assignment

This Agreement will be binding upon and enure for the benefit of the permitted assigns and, where applicable, successors in title, administrators, executors and personal representatives of the parties. The benefit of any provision of this Agreement may be enforced by the beneficial owners for the time being of the EDT Business or any of the Trading Assets, and accordingly the benefit of any provision in this Agreement may be assigned at any time and from time to time by the Purchaser and its successors in title without the consent of the Vendor.

6.12. Variations

This Agreement may not be released, varied, discharged, amended or supplemented, except by an instrument in writing executed by each party or a duly authorised representative of each party.

6.13. Financial Transfers


The Vendor declares for the purpose of the Financial Transfers Act, 1992 that it is not resident in any jurisdiction to which financial transfers (within the meaning of that Act) are restricted by order of the Minister for Finance in accordance with the provisions of that Act and does not hold any of the Trading Assets, and will not receive any part of the consideration, as nominee for any persons so resident, and the Purchaser declares for the purpose of that Act that it is not so resident, is not acquiring the Trading Assets as nominee for any persons so resident and that the Purchaser is not to its knowledge controlled directly or indirectly by persons so resident.

6.13.1. Recitals

The parties acknowledge that matters referred to in the recitals will not, in any way, give rise to any liability or cause of action against the Purchaser.


IN WITNESS whereof this Agreement has been entered into on the date and year first herein written.

SIGNED for and on behalf of
ELAN PHARMA INTERNATIONAL LIMITED



Director

SIGNED for and on behalf of
EDT PHARMA HOLDINGS LIMITED



Director

SCHEDULE 1

Excluded Assets

For the avoidance of doubt, the Excluded Assets of the Vendor means:

- (1) all those assets and records of the Vendor which do not form part of the EDT Business
- (2) all cash and bank accounts of the Vendor;
- (3) the Manufacturing Business; and
- (4) the statutory books of the Vendor.

SCHEDULE 2

Patents

Asset Transfer Agreement (EPI to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0002.US		ORD	USA	5250476	07986,646		08-Dec-1992	08-Dec-2012	IODINATED AROYLOXY CARBOXAMIDES
01.0003.US		ORD	USA	5361610	08038,371		29-Mar-1993	29-Mar-2013	IODINATED AROMATIC PROPANEDIAMIDES
01.0003.US	2	DIV	USA	5328404	08148,112		04-Nov-1993	29-Mar-2013	METHOD OF X-RAY IMAGING USING IODINATED AROMATIC PROPANEDIAMIDES
01.0004.US		ORD	USA	5295262	07997,804		04-Dec-1992	04-Dec-2012	USE OF IONIC CLOUD POINT MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
01.0005.US		ORD	USA	5302401	07987,679		09-Dec-1992	08-Dec-2012	METHOD TO REDUCE PARTICLE SIZE GROWTH DURING LYOPHILIZATION
01.0006.US	3	DIV	USA	5451993	08207,533		07-Mar-1994	18-Sep-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
01.0007.US		ORD	USA	5332879	07996,987		16-Dec-1992	16-Dec-2012	IODINATED AROYLOXY ESTERS
01.0007.US	2	CIP	USA	5469433	08261,794		30-Jun-1994	16-Dec-2012	IODINATED AROYLOXY ESTERS
01.0008.US		ORD	USA	5326552	07991,809		17-Dec-1992	17-Dec-2012	FORMULATIONS FOR NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH MOLECULAR WEIGHT NONIONIC SURFACTANTS
01.0008.US	2	DIV	USA	5447710	08242,492		10-May-1994	05-Sep-2012	METHOD OF MAKING NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH MOLECULAR WEIGHT NONIONIC SURFACTANTS
01.0009.US		ORD	USA	5330739	07985,416		04-Dec-1992	04-Dec-2012	IODINATED BENZOYL ACETALS AND METALS FOR X-RAY IMAGING
01.0010.US	2	DIV	USA	5470563	08240,309		10-May-1994	11-Dec-2012	METHOD OF PREPARING NANOPARTICLE COMPOSITIONS CONTAINING CHARGED PHOSPHOLIPIDS TO REDUCE AGGREGATION
01.0013.US		ORD	USA	5348688	07991,640		16-Dec-1992	16-Dec-2012	IODINATED WETTING AGENTS
01.0013.US		ORD	USA	5348702	07986,424		04-Dec-1992	04-Dec-2012	USE OF NON-IONIC CLOUD POINT MODIFIERS TO MINIMIZE NANOPARTICLE AGGREGATION DURING STERILIZATION
01.0015.US		ORD	USA	5352459	07991,839		16-Dec-1992	16-Dec-2012	USE OF PURIFIED SURFACE MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
01.0018.US	2	COR	USA	5384107	08295,595		08-Aug-1994	14-Dec-2012	IODINATED AROMATIC COMPOUNDS
01.0017.US	2	DIV	USA	5494684	08365,267		28-Dec-1994	27-Feb-2013	SURFACE MODIFIED ANTICANCER NANOPARTICLES WATER INSOLUBLE NON-MAGNETIC MANGANESE PARTICLES AS MAGNETIC RESONANCE CONTRAST ENHANCEMENT AGENTS
01.0018.US		ORD	USA	5407482	07991,893		17-Dec-1992	17-Dec-2012	PARTICLES AS MAGNETIC RESONANCE CONTRAST ENHANCEMENT AGENTS
01.0019.US		ORD	USA	5439824	07990,874		15-Dec-1992	15-Dec-2012	USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
01.0020.US		ORD	USA	5466440	08367,407		30-Dec-1994	30-Dec-2014	FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
01.0021.US	2	COR	USA	5543552	08534,145		22-Aug-1995	22-Aug-2015	NANOPARTICULATE DIAGNOSTIC MIXED CARBONIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case	Country	Patent	Application	Publication	Filing	Normal	Short Title / Subject Matter
	Case	Type		Number	Number	Number	Date	Expiry	Date
01.0021.US	3	ORD	USA	5472823	08/401,570		09-Mar-1995	09-Mar-2015	NANOPARTICULATE DIAGNOSTIC MIXED LIPIDIC AMYLIPOIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0021.US	4	ORD	USA	5573749	08/401,397		09-Mar-1995	09-Mar-2015	NANOPARTICULATE DIAGNOSTIC MIXED CARBOXYLIC AMYLIPOIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0022.US		ORD	USA	5488133	08/209,161		10-Mar-1994	10-Mar-2014	IODINATED AROYLOXY KETONES NANOPARTICULATE DIAGNOSTIC DIMERS AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0023.US		ORD	USA	5500204	08/386,788		10-Feb-1995	10-Feb-2015	CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0024.US		ORD	USA	5503723	08/395,531		06-Feb-1995	06-Feb-2015	ISOLATION OF ULTRA SMALL PARTICLES PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES
01.0025.US		ORD	USA	5510118	08/388,082		14-Feb-1995	14-Feb-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
01.0026.US	2	CON	USA	5518167	08/180,827		12-Jan-1994	12-Jan-2014	NANOPARTICULATE MSAID COMPOSITIONS
01.0027.US		ORD	USA	5518736	08/395,614		09-Feb-1995	09-Feb-2015	NANOPARTICULATE IODIPAMIDE DERIVATIVES FOR USE AS X-RAY CONTRAST AGENTS
01.0028.US		ORD	USA	5521218	08/440,794		15-May-1995	15-May-2015	NANOPARTICULATE DIAGNOSTIC DIATRIZOY ESTER X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0029.US		ORD	USA	5525328	08/265,550		24-Jun-1994	24-Jun-2014	METHOD OF PREPARING STABLE DRUG NANOPARTICLES
01.0030.US		ORD	USA	5534270	08/386,028		09-Feb-1995	09-Feb-2015	PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES
01.0031.US		ORD	USA	5543123	08/388,098		14-Feb-1995	14-Feb-2015	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
01.0033.US		ORD	USA	5571536	08/384,057		06-Feb-1995	06-Feb-2015	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
01.0033.US	2	ORD	USA	5580631	08/388,088		14-Feb-1995	14-Feb-2015	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS
01.0034.US		ORD	USA	5580932	08/370,865		10-Jan-1995	10-Jan-2015	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
01.0035.US		ORD	USA	5585188	08/393,972		24-Feb-1995	24-Feb-2015	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANO PARTICLES
01.0036.US	2	CIP	USA	5703194	08/727,863		08-Oct-1996	24-Feb-2015	SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS
01.0036.US		ORD	USA	5688448	08/273,022		24-Jan-1995	24-Jan-2015	DIAGNOSTIC IMAGING X-RAY CONTRAST AGENTS PEDISPERIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
01.0037.US		ORD	USA	5573750	08/447,155		22-May-1995	22-May-2015	
01.0038.US		ORD	USA	5573763	08/387,851		13-Feb-1995	13-Feb-2015	

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0039.US	ORD	USA	5505279	08/388,878		15-Feb-1995	15-Feb-2015	SITE-SPECIFIC ADHESION WITHIN THE GI TRACT USING NANOPARTICLES STABILIZED BY HIGH MOLECULAR WEIGHT, LINEAR POLY (ETHYLENE OXIDE) POLYMERS FORMULATIONS OF ORAL GASTROINTESTINAL THERAPEUTIC AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
01.0040.US	ORD	USA	5505126	08/388,518		30-Dec-1994	30-Dec-2014	BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER NANOPARTICLE COMPOSITIONS
01.0041.US	ORD	USA	5507143	08/287,082		26-Jun-1994	26-Jun-2014	SURFACTANTS AS STABILIZER COATINGS FOR MILLED NAPROXEN WITH HYDROXYPROPYL CELLULOSE
01.0042.US	ORD	USA	5591456	08/388,790		10-Feb-1995	10-Feb-2015	NOVEL BARIUM SALT FORMULATIONS STABILIZED BY NON-IONIC AND ANIONIC STABILIZERS
01.0043.US	ORD	USA	5593557	08/388,037		09-Feb-1995	09-Feb-2015	3-5-BIS ALKANOYL AMINO-2,4,6-TRIMETHACRYL ESTERS
01.0044.US	ORD	USA	5603916	08/447,132		22-May-1995	22-May-2015	SUGAR BASE SURFACTANT FOR NANOCRYSTALS FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS AND ORAL GASTROINTESTINAL THERAPEUTIC AGENTS
01.0045.US	2 CIP	USA	5622938	08/444,796		19-May-1995	09-Feb-2015	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0046.US	ORD	USA	5628981	08/388,841		30-Dec-1994	30-Dec-2014	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0048.US	2 CIP	USA	6432381	08/815,346	US 2001-0086617 A1	11-Mar-1997	30-Dec-2014	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0048.US	3 CON	USA		10/175,851	US 2003-0054045 A1	21-Jun-2002	30-Dec-2014	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0047.US	ORD	USA	5682883	08/370,936		10-Jan-1995	10-Jan-2015	MICROPRECIPITATION OF MICRO-NANOPARTICULATE PHARMACEUTICAL AGENTS
01.0049.US	ORD	USA	5685331	08/370,996		10-Jan-1995	10-Jan-2015	CO-MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS WITH CRYSTAL GROWTH MODIFIERS
01.0050.US	ORD	USA	5688196	08/677,703		10-Jul-1996	10-Jul-2016	NOVEL 3-AMIDO-TRIMETHACRYL ESTERS AS X-RAY CONTRAST AGENTS
01.0051.US	CON	USA	5670136	08/566,363		18-Jan-1996	23-Sep-2014	2,4,6-TRIMETHACRYL-SUBSTITUTED-AMINO-ISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTIC IMAGING
01.0052.US	ORD	USA	5716642	08/270,926		10-Jan-1995	10-Feb-2015	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS USING SURFACE ACTIVE MATERIAL DERIVED FROM SIMILAR PHARMAC
01.0053.US	ORD	USA	5718388	08/249,787		25-May-1994	17-Feb-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
01.0054.US	ORD	USA	5719918	08/393,943		25-May-1994	17-Feb-2015	NANOPARTICLES CONTAINING THE N-EMANTIONER OF IBUPROFEN
01.0056.US	ORD	USA	5747001	08/293,973		24-Feb-1995	05-May-2015	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICLE DISPERSIONS

Asset Transfer Agreement (EPIL to EDT Pharms Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Class Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0066.US	2	ORD	USA	5834025	08/626,754		14-Aug-1998	14-Aug-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
01.0066.US	3	REI	USA	RE41,884 E	12,027,100		06-Feb-2008	14-Aug-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
01.0067.US	2	CON	USA	5962999	08/401,539		15-Jun-1995	25-May-2014	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
01.0068.US		ORD	USA	5936030	08/936,819		14-Aug-1997	10-Aug-2016	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
01.0069.US	2	CIP	USA	6045829	08/590,602		08-Jul-1997	13-Feb-2017	METHODS OF MAKING NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
01.0069.US	4	DIV	USA	6068858	08/235,493		05-Jan-1999	09-Jul-2017	FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
01.0069.US	4	CIP	USA	6221430	09/225,498		06-Jan-1998	13-Feb-2017	METHODS OF TREATING MAMMALS USING NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS
01.0069.US		ORD	USA	6153225	08/154,422		13-Aug-1998	13-Aug-2018	JECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
01.0061.US		ORD	USA	6165998	08/148,332		04-Sep-1998	04-Sep-2018	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
01.0062.US		CON	USA	6264922	08/948,216		06-Oct-1997	24-Feb-2015	NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS
01.0062.US	2	DIV	USA		08/577,489		22-May-2000	24-Feb-2015	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0062.US	3	CON	USA		12/061,670	US 2006/027404A1	18-Apr-2006	24-Feb-2015	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US		ORD	USA	7,521,066 B2	08/190,138	US 2002/0102294 A1	12-Nov-1998	12-Apr-2022	DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US	2	DIV	USA	6811787	08/597,736		19-Jun-2000	12-Nov-2018	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US	3	CON	USA		12/020,431	US 2009/0181100 A1	26-Jan-2009	12-Nov-2018	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0064.US		ORD	USA	6270606	08/261,151		03-Mar-1999	03-Mar-2019	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
01.0065.US		ORD	USA	6267969	08/263,934		06-Mar-1999	06-Mar-2019	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS

Asses. Transfer Agreement (Eph. to EDT Pharma Holdings) - 2 August 2017
 Schedule Z: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Applicants Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0066.US	ORD	USA	6626504	097392,557		09-Sep-1999	09-Sep-2019	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPROME AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
01.0067.US	2 CIP	USA		097337,675	US 2002-0012675 A1	22-Jun-1999	01-Oct-2018	CONTROLLED-RELEASE NANOPARTICULATE COMPOSITIONS
01.0067.US	4 CON	USA		11979,231	US 2006-0124393 A1	31-Oct-2007	01-Oct-2016	CONTROLLED-RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
01.0067.US	6 CON	USA		12483,188	US 2008-0287019 A1	11-Jun-2009	22-Jun-2019	NANOPARTICULATE ANTICONDYLANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
01.0067.US	CON	USA		13102,785		06-May-2001	01-Oct-2018	CONTROLLED-RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
01.0068.US	ORD	USA	6428814	08414,159	US 2002-0065082 A1	08-Oct-1999	08-Oct-2019	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0068.US	2 DIV	USA	7288287	10004,506	US 2003-0110861 A1	08-Oct-1999	29-May-2021	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0068.US	3 DIV	USA	7950295	11898,274	US 2008-0303285 A1	11-Sep-2007	08-Oct-2018	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0069.US	2 ORD	USA	6431475	09563,663	US 2002-0145062 A1	31-May-2000	26-Jul-2020	SMALL-SCALE MILL AND METHOD THEREOF
01.0069.US	3 DIV	USA	6745862	10937,566	US 2004-0251322 A1	19-Oct-2001	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
01.0069.US	4 CON	USA	6991181	10883,045	US 2004-0251322 A1	28-Apr-2004	30-Jun-2023	SMALL-SCALE MILL AND METHOD THEREOF
01.0070.US	ORD	USA	6316029	09572,981	US 2004-0057983 A1	16-May-2000	16-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0070.US	2 CON	USA		10867,470	US 2004-0057983 A1	23-Sep-2003	18-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0070.US	4 CON	USA		13068,706	US 2008-0213371 A1	11-Feb-2008	18-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0071.US	ORD	USA	6375986	09566,538		21-Sep-2000	21-Sep-2020	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
01.0071.US	3 CON	USA	6592903	10975,443	US 2002-0110597 A1	15-Feb-2003	21-Sep-2020	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
01.0072.US	2 CIP	USA	6988529	10246,373	US 2003-0108616 A1	18-Jan-2003	21-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
01.0072.US	3 DIV	USA	7244451	11213,765	US 2007-0141158 A1	30-Aug-2005	05-Feb-2021	METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
01.0077.US	2 ORD	USA	6582285	09843,619	US 2001-0038664 A1	28-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING

Asset Transfer Agreement (EPFL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case	Country	Patent	Application	Publication	Filing	Normal	Short Title / Subject Matter
	Case	Type		Number	Number	Number	Date	Expiry	
01.0078.US	2	ORD	USA	107546.751	US 2003-0095928 A1	19-Sep-2002	19-Sep-2022		NANOPARTICULATE COMPOSITIONS OF INSULIN
01.0079.US	2	ORD	USA	6742734	US 2002-0179758 A1	04-Jun-2002	06-Aug-2022		SYSTEM AND METHOD FOR MILLING MATERIALS
01.0078.US	3	CIP	USA	6976647	US 2004-0164194 A1	11-Dec-2003	04-Jun-2023		SYSTEM AND METHOD FOR MILLING MATERIALS
01.0078.US	5	DIV	USA	7575184	US 2009-0025807 A1	03-Aug-2007	04-Aug-2022		SYSTEM AND METHOD FOR MILLING MATERIALS
01.0080.US		ORD	USA	030352.032	US 2005-0054042 A1	14-Sep-2001	14-Sep-2021		STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	3	CON	USA	115602.158	US 2007-0224379 A1	21-May-2007	14-Sep-2021		STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	4	CON	USA	118979.251	US 2009-0175951 A1	31-Oct-2007	14-Sep-2021		STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	5	CON	USA	121213.443	US 2009-0185889 A1	15-May-2008	14-Sep-2021		STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0083.US	2	ORD	USA	7456283	US 2009-0074875 A1	04-Feb-2003	10-Jul-2026		NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
01.0083.US	3	CON	USA	122292.091	US 2009-0074875 A1	12-Nov-2006	04-Feb-2023		NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
01.0086.US	3	CIP	USA	112775.069	US 2008-0193920 A1	07-Dec-2005	21-Sep-2020		NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
01.0088.US		ORD	USA	107035.324	US 2009-0129242 A1	04-Jan-2002	04-Jan-2022		STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
01.0089.US	2	ORD	USA	106659.706	US 2008-0031691 A1	11-Sep-2003	12-Nov-2024		GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0091.US	4	DIV	USA	119226.290	US 2008-0050461 A1	30-Oct-2007	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	5	DIV	USA	119228.278	US 2008-0107741 A1	30-Oct-2007	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	6	DIV	USA	119228.289	US 2008-0236732 A1	30-Oct-2007	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	7	CIP	USA	120076.247	US 2008-0220075 A1	14-Mar-2008	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	8	CON	USA	121117.982	US 2009-0279949 A1	09-May-2008	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	9	CON	USA	128670.722	US 2010-0322852 A1	27-Aug-2010	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	10	CON	USA	128707.746	US 2010-0322953 A1	27-Aug-2010	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	11	CON	USA	129870.789	US 2010-0329976 A1	27-Aug-2010	20-Mar-2023		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Asset Transfer Agreement (EPH, to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0092.US	3 ORD	USA	* 7101576	10442.569	US 2003-0219490 A1	14-Apr-2003	12-Apr-2024	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	4 CIP	USA		10478.623	US 2005-0009707 A1	29-Jun-2004	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	5 CIP	USA		11093.149	US 2005-0233001 A1	30-Mar-2005	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	6 CIP	USA		11072.556	US 2010-0228989 A1	22-Jun-2006		NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	8 CON	USA		12025.557	US 2010-0266705 A1	29-Jun-2010	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0093.US	3 CIP	USA	* 7276249	10444.056	US 2005-0276974 A1	20-May-2005	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	4 DIV	USA	* 7300802	10692.855	US 2004-1005805B A1	27-Oct-2003	21-Feb-2023	METHODS OF TREATMENT USING NANOPARTICULATE FENOFIBRATE COMPOSITIONS
01.0093.US	11 CIP	USA		11710.607	US 2007-0264348 A1	26-Feb-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	12 CON	USA		11802.542	US 2007-0296115 A1	23-May-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	13 CON	USA		11802.567	US 2006-0095861 A1	23-May-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	15 CON	USA		11879.230	US 2008-0139424 A1	31-Oct-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	16 CIP	USA		12068.497	US 2008-0241070 A1	28-Mar-2008	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0098.US	4 CON	USA		11367.716	US 2011-0027371 A1	06-Mar-2006	01-Oct-2018	NANOPARTICULATE STATIN FORMULATIONS & NOVEL STATIN COMBINATIONS
01.0098.US	2 ORD	USA	7,763,278 B2	10457.811	US 2003-0232796 A1	10-Jun-2003	03-Mar-2024	NANOPARTICULATE POLYCOSSANOL FORMULATIONS AND NOVEL POLYCOSSANOL COMBINATIONS
01.0098.US	3 DIV	USA		12704.426	US 2010-0143062 A1	11-Feb-2010	10-Jun-2023	NANOPARTICULATE POLYCOSSANOL FORMULATIONS AND NOVEL POLYCOSSANOL COMBINATIONS
01.0098.US	2 ORD	USA		10784.900	US 2004-0229038 A1	24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
01.0098.US	3 CIP	USA	*	12768.503	US 2010-0297252 A1	26-May-2010	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
01.0100.US	2 ORD	USA		10706.227	US 2004-0156995 A1	12-Nov-2003	12-Nov-2023	SOLID DOSAGE FORMS COMPRISING PULLULAN LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
01.0102.US	2 ORD	USA		10610.539	US 2004-0258757 A1	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
01.0102.US	3 DIV	USA		13044.450	US 2004-0258757 A1	09-Mar-2011		NANOPARTICULATE ACTIVE AGENTS
01.0103.US	2 ORD	USA		10654.610	US 2004-0105778 A1	04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS

Asset Transfer Agreement (EPRI to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Class Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0105.US	2	CIP	USA	7,198,795 B2	10/323,736	US 2004-0029099 A1	20-Dec-2003	07-Jan-2021	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0106.US	2	CON	USA	7865738	11/650,412		08-Jan-2007	21-Sep-2020	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0106.US	3	CON	USA		12/729,019	US 2010-0178948 A1	22-Mar-2010	21-Sep-2020	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0106.US	4	ORD	USA	7390306	10/766,960	US 2004-0253758 A1	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
01.0107.US	2	ORD	USA		10/768,194	US 2004-0306833 A1	02-Feb-2004		NOVEL FLUTICASONIUM FORMULATIONS
01.0107.US	2	CON	USA		13/159,299		22-Jul-2007	02/02/2024	NOVEL FLUTICASONIUM FORMULATIONS
01.0108.US	2	CIP	USA		10/430,827	US 2004-0105889 A1	23-Apr-2003	14-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
01.0108.US	3	CON	USA		11/979,253	US 2009-0153585 A1	31-Oct-2007	14-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
01.0108.US	2	ORD	USA	7842232	10/651,681	US 2010-0255102 A1	24-May-2004	29-Jun-2027	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
01.0110.US	2	ORD	USA		10/865,405	US 2005-0042177 A1	21-Jul-2004		NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
01.0112.US		CIP	USA		10/897,703	US 2004-0156872 A1	31-Oct-2003		NOVEL NIMESULIDE COMPOSITIONS
01.0112.US		CON	USA		13/193,545		20-Jul-2011	16/05/2021	NOVEL NIMESULIDE COMPOSITIONS
01.0114.US	6	CON	USA		13/292,092	US 2009-0074873 A1	12-Feb-2008	24-Feb-2015	NANOPARTICULATE BECLMETHASONE DIPROPIONATE COMPOSITIONS
01.0115.US		CIP	USA		10/697,716	US 2004-0141925 A1	31-Oct-2003	16-Jul-2023	NOVEL TRIAMCINOLONE COMPOSITIONS
01.0116.US		CIP	USA		10/701,064	US 2005-0019412 A1	05-Nov-2003		NOVEL GLIPIZIDE COMPOSITIONS
01.0117.US		CIP	USA		10/712,269	US 2004-0115134 A1	14-Nov-2003	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0117.US	2	CON	USA		11/860,720	US 2009-0047209 A1	31-Oct-2007	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0117.US	3	CON	USA		13/292,386	US 2009-0104273 A1	16-Nov-2008	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0118.US		CIP	USA		10/677,857	US 2004-0101586 A1	03-Oct-2003		NOVEL BENZOYL PEROXIDE COMPOSITIONS

Asset Transfer Agreement (EPL to EDI Pharms Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0121.US	2	ORD	USA	7679360	10979,695	US 2005-0238725 A1	02-Nov-2004	30-Feb-2026	NANOPARTICULATE COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER
01.0122.US	2	ORD	USA		10979,793	US 2005-0147664 A1	03-Nov-2004	03-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETED NANOPARTICULATE ACTIVE AGENT DELIVERY
01.0123.US	2	ORD	USA	7910577	11274,667	US 2006-0154916 A1	16-Nov-2005	26-Jan-2029	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
01.0123.US	3	CRP	USA		12333,293		12-Nov-2006	16-Nov-2025	NANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS
01.0123.US	4	DRY	USA		13024,315		09-Feb-2011	16-Nov-2023	NANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS
01.0124.US	3	CON	USA		12732,895	US 2009-0035366 A1	25-Sep-2008		NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
01.0125.US	3	ORD	USA		11633,088		04-Dec-2006	04-Dec-2026	NIVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
01.0132.US	2	ORD	USA		11377,850	US 2006-0210639 A1	17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
01.0134.US	2	ORD	USA		11378,554	US 2006-0210639 A1	16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE RANUNOLIPREFESIVE COMPOUNDS
01.0135.US	2	ORD	USA		11387,668	US 2006-0216353 A1	23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
01.0137.US	2	ORD	USA		11402,264		13-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
01.0140.US	2	ORD	USA		11403,257	US 2006-0246141 A1	12-Apr-2006	12-Apr-2026	NANOPARTICULATE LIPASE INHIBITOR FORMULATIONS
01.0143.US	2	ORD	USA		11436,867		19-May-2006	19-May-2026	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
01.0143.US	3	CON	USA		11880,719		31-Oct-2007	19-May-2026	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
01.0149.US	2	ORD	USA		11437,833	US 2010-0126439 A1	22-May-2006	22-May-2026	NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS
01.0151.US	2	CRP	USA		12352,436	US 2008-0220074 A1	30-Mar-2008	04-Sep-2023	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCEXAXEL COMPOSITIONS AND METHOD OF MAKING SAME
01.0152.US	2	ORD	USA		11353,266	US 2007-0202160 A1	26-Feb-2006	26-Feb-2026	NANOPARTICULATE CARVEDILOL FORMULATIONS
01.0153.US	2	ORD	USA		11275,775	US 2007-0178051 A1	27-Jan-2006		STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
01.0154.US	5	CON	USA		12071,949	US 2008-0152720 A1	27-Feb-2008	18-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
01.0154.US	6	CON	USA		12484,073	US 2009-0252806 A1	12-Jun-2009	16-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
01.0154.US	4	DRY	USA		13039,243		02-Mar-2011	21-Dec-2025	NANOPARTICULATE BICALUTAMIDE FORMULATIONS

Asset Transfer Agreement (EPH to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0166.US	2	ORD	USA	115961055	US 2006-0180586 A1	US 2006-0180586	04-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
01.0167.US	2	ORD	USA	11354249	US 2006-0198886 A1	US 2006-0198886	15-Feb-2006		AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
01.0167.US	3	CON	USA	12544197	US 2009-0304881 A1	US 2009-0304881	19-Aug-2009	15-Feb-2028	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
01.0168.US	2	ORD	USA	11535536	US 2006-0165886 A1	US 2006-0165886	05-Jan-2006		NANOPARTICULATE CANDESARTAN FORMULATIONS
01.0168.US	2	ORD	USA	11537227	US 2006-0204588 A1	US 2006-0204588	10-Mar-2006	10-Mar-2026	FORMULATIONS OF A NANOPARTICULATE FINASTERIDE, DUTASTERIDE OR TAMUSULOSIN HYDROCHLORIDE, AND MIXTURES THEREOF
01.0168.US	2	ORD	USA	11446569	US 2007-0342046 A1	US 2007-0342046	06-Jun-2006	05-Jun-2026	NANOPARTICULATE BENIDIPINE COMPOSITIONS
01.0167.US	2	ORD	USA	11446564	US 2006-0262214 A1	US 2006-0262214	06-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN FORMULATIONS
01.0168.US	2	ORD	USA	11446566	US 2006-0375372 A1	US 2006-0375372	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
01.0169.US	2	ORD	USA	11448384	US 2007-0699371 A1	US 2007-0699371	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
01.0172.US	3	ORD	USA	11592427			22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
01.0174.US	2	ORD	USA	11481257			08-Jul-2006	08-Jul-2026	NANOPARTICULATE CLAZOTHROMYCIN FORMULATIONS
01.0176.US	2	ORD	USA	11620169	US 2007-0104792 A1	US 2007-0104792	13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
01.0177.US	2	ORD	USA	11520088	US 2007-0146100 A1	US 2007-0146100	13-Sep-2006	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIPRAZOLE
01.0178.US	1	ORD	USA	11761900			12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
01.0180.US	2	ORD	USA	11775092	US 2006-0210374 A1	US 2006-0210374	09-Jul-2007	09-Jul-2027	NANOPARTICULATE FORMULATIONS OF SCRAFENIB TOSYLATE
01.2004.US	2	ORD	USA	11729507			16-May-2005	16-May-2025	NANOPARTICLE DISPERSION CONTAINING LACTAM COMPOUND
01.2007.US	2	ORD	USA	12931052			09-Dec-2008	09-Dec-2028	NANOPARTICULATE ARIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
01.2011.US	3	ORD	France	113500			26-May-2010	26-May-2030	NANOPARTICULATE ANTICANDER COMPOSITIONS AND METHODS FOR MAKING THE SAME
01.2011.US	3	ORD	USA	12329566	2009-0311335 A1	2009-0311335 A1	24-Feb-2009	24-Feb-2029	COMBINATION OF A TRITIAN AND AN NSAIL
01.2013.US	2	ORD	USA	13110947			18-May-2007	18-May-2031	NANOPARTICULATE CINACALCET COMPOSITIONS CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
02.1007.US	2	ORD	USA	11262672			31-Oct-2006	31-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
02.1007.US	2	CIP	USA	11373029	US 2007-0098791 A1	US 2007-0098791 A1	10-Mar-2006	31-Oct-2025	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
02.1008.US	2	ORD	USA	11569483	US 2006-0266045 A1	US 2006-0266045 A1	04-Feb-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
02.1009.US	2	ORD	USA		11229,993	US 2008-0259596 A1	11-Jan-2008	11-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ACYLANILIDE
02.1011.US	2	ORD	USA		11268,841		29-Jan-2007	14-Feb-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM
02.1012.US	2	ORD	USA		11571,379		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
02.1013.US	2	ORD	USA		11568,202	US 2007-012481 A1	09-Nov-2006	01-Nov-2015	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
02.1103.US		CIP	USA		11568,925		16-Nov-2006	01-Nov-2019	MODIFIED RELEASE LIDOCAINE COMPOSITIONS
02.1107.US	2	PCT	USA		11422,226	US 2008-0118556 A1	05-Jun-2006	01-Nov-2019	MODIFIED RELEASE COMPOSITIONS CONTAINING A COMBINATION OF CARBIDOPA, LEVODOPA AND ENTACAPONE
02.1200.US	4	CON	USA		08287,392		16-Sep-1994	09-Apr-2013	CONTROLLED RELEASE PHARMACEUTICAL FORMULATION
02.1255.US		ORD	USA		09473,508		07-Jan-1995	07-Jan-2015	CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
02.1301.US	4	CON	USA		07521,459		28-Jul-1992	15-Nov-2011	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1307.US	5	DIV	USA		08234,864		04-Nov-1994	01-Apr-2014	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1303.US	3	CON	USA		08264,401		19-May-1993	22-Jul-2012	DILTIAZEM FORMULATION AND METHODS OF TREATMENT OF FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1608.US	2	CON	USA		08073,651		07-Jan-1993	08-Dec-2011	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	3	DIV	USA		08323,166		24-Oct-1994	30-Jul-2019	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1808.US	4	DIV	USA		09473,506		07-Jun-1995	03-Dec-2013	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1807.US		ORD	USA		09244,094		13-May-1994	09-Jul-2013	PASSIVE TRANSDERMAL DEVICE WITH CONTROLLED DRUG DELIVERY
02.1809.US	2	ORD	USA		08977,965		25-Nov-1997	25-Nov-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
02.1810.US	2	CON	USA		09566,646		08-May-2000	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
02.1816E.US	3	CON	USA		09680,425	US 2002-0064907 A1	07-May-2001	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPPHENIDATE)
02.1816E.US	4	CON	USA		10631,754	US 2003-0128237 A1	30-Dec-2002	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPPHENIDATE)
02.1816E.US	5	CON	USA		10354,483	US 2003-0170304 A1	30-Jan-2003	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPPHENIDATE)
02.1816E.US	6	CON	USA		10627,689	US 2004-0197402 A1	19-Apr-2004	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPPHENIDATE)
02.1816E.US	7	CIP	USA		11372,857	US 2006-0340105 A1	10-Mar-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPPHENIDATE)

Asset Transfer Agreement (EPIL to ECT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
02.1819.US	2 ORD	USA	7465482	097744.159		19-Apr-2001	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS
02.1830.US	2 ORD	USA	7021183	10482.058	US 2005-0003550 A1	08-Apr-2004	09-Oct-2023	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM PHARMACEUTICALS
02.1831AC.US	5 DIV	USA		12626.001	US 2010-0272807	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1832AC.US	6 DIV	USA		12626.005	US 2010-0272796	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1832AC.US	7 DIV	USA		12626.036	US 2010-0272796	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1860.US	2 ORD	USA		115663.291	US 2010-0136106 A1	15-Jan-2010	07-Jun-2025	MODIFIED RELEASE FAMCICLOVIR COMPOSITIONS
02.1902.US	2 ORD	USA		115669.481	US 2009-0287397 A1	21-Nov-2006		MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
02.2098.US	ORD	PCT		PCT/US2011027736		10-Mar-2011		ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
02.2098.US	6 ORD	USA		13044.226		09-Mar-2011		ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
03.0001	ORD	Argentina	AR 255241	AR 255241		24-Jan-1992	24-Sep-2016	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Australia	654836	654836	AU1014792	13-Jan-1992	13-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Canada	2068432	2068432		15-Jan-1992	15-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Chile	46.768	92974		24-Jan-1992	23-Jul-2025	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Finland	108333	108333		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Hungary	221.586 B1	221.586		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Ireland	53410	52-0217		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Israel	100754	100754		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Japan	3602546B2	1992-011225		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Korea, Republic of	203261	203261		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Mexico	176345	176345		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	New Zealand	241352	241352		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Norway	303688	303688		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Russian Federation	2066553	2066553		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Singapore	55104	55104		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001	ORD	Taiwan	M1-071312	M1-071312		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0002	ORD	Israel	107704	107704		20-Sep-1993	20-Sep-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0002	ORD	Korea, Republic of	303358	9321154		13-Oct-1993	13-Oct-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0002	ORD	Taiwan	M1-072517	M1-072517		13-Oct-1993	13-Oct-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0006	ORD	EPC	498482	62200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0006	EPC	France	498482	62200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0006	EPC	Germany	69229825.4	92200152.4	698482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0008		EPC	Italy	498482	92200152.4	498482	30-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0009		EPC	United Kingdom	498482	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0017		ORD	Canada	3088242	3088242	3088242	11-Jun-1993	11-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		ORD	EPC	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		EPC	France	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		EPC	Germany	69328136	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		EPC	Italy	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017	2	INV	Japan	3008-136475			29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017	3	DRV	Japan	2010-186927	2010-285324		24-Aug-2010	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		ORD	Mexico	265097	933950		30-Jun-1993	30-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017		EPC	United Kingdom	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0019		ORD	Canada	2108192	2108192	2108192	12-Oct-1993	12-Oct-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019		ORD	EPC	EP 0 602 702	93203365.7	EP 0 602 702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019		EPC	France	602702	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019		EPC	Germany	69324455.9	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019		ORD	Korea, Republic of	300360	22700093		29-Oct-1993	29-Oct-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019		EPC	United Kingdom	602702	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0026		ORD	Argentina	251001	325206		04-Oct-1993	16-Sep-2012	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026		ORD	Australia	660853	4667093		29-Sep-1993	29-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026		EPC	Austria	E193646	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026		EPC	Belgium	EP 0 800 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026		ORD	Canada	2107400	2107400		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EBT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0026	ORD	Czech Republic	284802	PV02277-83		26-Oct-1993	26-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Denmark	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	EPC	EP 0 600 528	93202795.6	EP 0 600 528	30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Finland	106339	934320		01-Oct-1993	01-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	France	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Germany	6952816.9	93302795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Greece	28306401912	3034227		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Hungary	210826	P9302779	67684	01-Oct-1993	01-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Ireland	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Italy	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Korea, Republic of	312798	Z226493		26-Oct-1993	26-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Liechtenstein	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Luxembourg	EP 0 600 528	93302795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Malaysia	MY-109419A	P16302659		08-Oct-1993	08-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Mexico	169779	936443		15-Oct-1993	15-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Morocco	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Netherlands	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	New Zealand	249913	348813		29-Sep-1993	29-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Philippines	31116	47959		11-Oct-1993	23-Feb-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Portugal	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Slovakia	381078	PV130189		19-Nov-1993	19-Nov-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Spain	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0026	EPC	Sweden	EP 0 800 528	93202785.8		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	Switzerland	EP 0 800 528	93202786.8		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Taiwan	NL-089478	82108254		06-Oct-1993	06-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Ukraine		93000406		28-Oct-1993	28-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	EPC	United Kingdom	EP 0 800 528	93202785.8		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026	ORD	Venezuela	55519	148493		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0027	PCT	Canada	2212779	2212779		18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	PCT	Canada	2212779	96805181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	EPC	France	EP 0 808 156	96805181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	EPC	Germany	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	EPC	Italy	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	PCT	Japan	3710818	1996-6524388		18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027	EPC	United Kingdom	EP 0 808 156	96805181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0032	PCT	Canada	2118517	2118517		01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	PCT	EPC	EP 0 644 755	93914224.6	EP 0 644 755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	EPC	France	644755	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	EPC	Germany	68309056.1	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	EPC	Italy	644755	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	PCT	Japan	4435590	960550181.5	2038-501073	09-Jun-1993	09-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	ORD	Mexico	203188	933452		01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032	EPC	United Kingdom	EP 0 644 755	93914224.6	EP 0 644 755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0036	PCT	Canada	2213663	2213663		22-Feb-1996	22-Feb-2016	MODIFIERS FOR NANOPARTICLES
03.0036	PCT	EPC	EP 0 810 855	96907063.9	EP 0 810 855	22-Feb-1996	22-Feb-2016	MODIFIERS FOR NANOPARTICLES
03.0036	EPC	France	810855	96907063.9	810855	22-Feb-1996	22-Feb-2016	MODIFIERS FOR NANOPARTICLES
03.0036	EPC	Germany	89628640	96907063.8	EP 0 810 855	22-Feb-1996	22-Feb-2016	MODIFIERS FOR NANOPARTICLES
03.0036	EPC	Italy	810855	96907063.8	810855	22-Feb-1996	22-Feb-2016	MODIFIERS FOR NANOPARTICLES

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0038	EPC	United Kingdom	EP 0 810 855	96907083.8	EP 0 810 855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0038	PCT	Canada	2212803	2212803	KCPRO042	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	PCT	EPC	812187	96804812.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	EPC	France	812187	96804812.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	EPC	Germany	96927835	96904812.7	EP 0 812 187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	EPC	Italy	812187	96904812.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	PCT	Japan		1996-6528046				REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	4	Japan		2010-145729	2010-241820	28-Jul-2010	09-Feb-2015	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038	EPC	United Kingdom	EP 0 812 187	96904812.7	EP 0 812 187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0053	ORD	Argentina	AR253558	331937		04-May-1995	25-Aug-2014	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Austria	E208191	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Belgium	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	PCT	Canada	2180134	2180134	2180134	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Denmark	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	PCT	EPC	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	France	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Germany	69523781	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Greece	20020400382	3038147	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Ireland	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	ORD	Israel	113851	113851		25-May-1995	25-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Italy	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	PCT	Japan	3987294	1995-630317		08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0053	EPC	Luxembourg	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	ORD	Malaysia	MY-113559-A	P185001375		25-May-1995	30-Apr-2017	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Minisco	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Netherlands	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	ORD	Philippines	31487	50574		24-May-1995	03-Nov-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Portugal	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Spain	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Sweden	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	Switzerland	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	ORD	Taiwan	88-142783	84103642	46297	13-Apr-1995	13-Apr-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	EPC	United Kingdom	EP 0 804 161	95919062	EP 0 804 161	06-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053	ORD	Venezuela	58558	0054-95	413	25-May-1995	25-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0055	PCT	Canada		2213660	2213660	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	PCT	EPC	EP 0 810 854	96306567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	2	EPC	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	EPC	France	EP 0 810 854	96306567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	2	France	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	EPC	Germany	68634037	96306567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	2	Germany	68637288	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	2	Ireland	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	EPC	Italy	EP 0 810 854	96306567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055	3	Italy	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS

Asset Transfer Agreement (EPN to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0055.		PCT	Japan	4494249	1996-6325799		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	Spain	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.		EPC	United Kingdom	EP 0 810 854	98026587.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	United Kingdom		3018236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0056.		PCT	Canada	2232879	2232879	2232879	25-Sep-1996	25-Sep-2016	NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0056.		PCT	EPC		96352321.1	EP 0 659 604	25-Sep-1996	25-Sep-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0056.	2	DIV	EPC		10181610.7	EP 2 276 094	24-Sep-2010	25-Sep-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0057.		ORD	Argentina	AR 254487 V1	381939		04-May-1995	29-Sep-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Austria	199601	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Belgium	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		PCT	Canada	2190966	2190966	2190966	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Denmark	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		PCT	EPC	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	France	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Germany	68618881.6	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Greece	3033040	3033040	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Ireland	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		ORD	Israel	113852	113852		25-May-1995	25-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Italy	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.		EPC	Liechtenstein	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Number	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0057	EPC	EP 0 760 653	Luxembourg	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	ORD	MY-112458-A	Malaysia	MY-112458-A	P95001374		24-May-1995	30-Jun-2016	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Monaco	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Netherlands	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	ORD	11995-50573	Philippines	11995-50573	1-1995-50573		24-May-1995	02-Mar-2018	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Portugal	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Spain	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Sweden	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	Switzerland	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	ORD	88-112433	Taiwan	88-112433	84104440	884224	03-May-1995	03-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	EPC	EP 0 760 653	United Kingdom	EP 0 760 653	95919628.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057	ORD	57612	Venezuela	57612	0853-85		25-May-1995	26-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0058	ORD	253886	Argentina	253886	253886		24-Feb-1995	09-Sep-2014	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058	PCT	2207569	Canada	2207569	2207569	2207569	21-Dec-1994	21-Dec-2014	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058	ORD	112136	Israel	112136	112136		29-Dec-1994	23-Dec-2014	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058	ORD	203191	Mexico	203191	951133		26-Feb-1995	28-Feb-2015	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058	ORD	11995-50650	Philippines	11995-50650	50650		03-Jul-1995	14-Jun-2013	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058	ORD	3282877	United Kingdom	3282877	2282877		30-Oct-1993	30-Oct-2013	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0059	PCT	2295588	Canada	2295588	2295588	2295588	08-Jul-1998	09-Jul-2018	MANCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSE SURFACE STABILIZERS
03.0059	PCT	EP 1 002 065	EPC	EP 1 002 065	Validation of EP		09-Jul-1998	09-Jul-2018	MANCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSE SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS

Asses Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

ESI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0059		PCT	France	EP 1 002 065	Validation of EP		09-Jul-1999	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0060		PCT	Germany	69831677	99931608.2		09-Jul-1999	09-Jul-2019	IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059		PCT	Italy	EP 1 002 065	Validation of EP		09-Jul-1999	09-Jul-2018	IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059		PCT	Japan		2000-502163	2010-47579	09-Jul-1999	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059	2	Div	Japan		2009-229598		09-Jul-1999	09-Jul-2018	METHODS OF MAKING SUCH FORMULATIONS
03.0059		PCT	United Kingdom	EP 1 002 065	Validation of EP		09-Jul-1999	09-Jul-2018	IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0060		PCT	Canada	2 340 221	2 340 221	2 340 221	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060		PCT	EPC	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060		EPC	France	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060		EPC	Germany	69907213	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060		EPC	Italy	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060		EPC	United Kingdom	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0061		PCT	Canada	2342309	2342309	2342309	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061		PCT	EPC	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061		EPC	France	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061		EPC	Germany	EP 1 109 536	DE1996002046	DE599020460	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0061.	EPC	Italy	EP 1 109 536	98943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061.	PCT	Japan	3812345	3000-668481T	2002-524413T	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061.	EPC	United Kingdom	EP 1 109 536	98943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0062.	PCT	Canada	2213638	2213638	KOPROOMZ	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0062.	PCT	Japan	4494247	Heib8-525736		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0062.	2	Japan		2007-230718		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0063.	EPP	Austria	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Belgium	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	PCT	Canada	2350374	2350374	2350374	12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Cyprus, Republic of	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Denmark	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	PCT	EPC	EP 1 128 814	98956981.7	EP 1 128 814	12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	2	EPC	EP 1 128 814	10179594	EP 2 263 652	27-Sep-2010	13-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	2	EPC	EP 1 128 814	10179594	EP 2 263 652	27-Sep-2010	13-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Finland	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	France	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Germany	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Germany	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Greece	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Ireland	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Italy	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	PCT	Japan	EP 1 128 814	2006-560364		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Liechtenstein	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Luxembourg	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Monaco	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Netherlands	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Portugal	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Spain	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Sweden	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	Switzerland	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	EPP	United Kingdom	EP 1 128 814	98956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0064.	PCT	Canada	2362508	2362508	KOPROOM2	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.	PCT	EPC	EP 1 156 788	913448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.	EPC	France	EP 1 156 788	913448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.	EPC	Germany	EP 1 156 788	913448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.	EPC	Italy	EP 1 156 788	913448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.	PCT	Japan	4380925	2000-802040		14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule Z: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0064	EPC	United Kingdom	EP 1 156 788	913449.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0065	PCT	Canada	2367096	2367096	2367096	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0066	PCT	EPC	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0067	EPC	France	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0068	EPC	Germany	60000623	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0069	EPC	Italy	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0070	PCT	Japan		2000-600663		14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0071	Div	Japan		2009-223000	2010-31026	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0072	EPC	United Kingdom	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0073	PCT	Canada	2384670	2384670	2384670	07-Sep-2000	07-Sep-2020	AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0074	PCT	EPC	EP 1 210 104	959365.5	EP 1 210 104	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0075	PCT	France	EP 1 210 104	Validation of EP	EP 1 210 104	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0076	PCT	Germany	60027171	Validation of EP	EP 1 210 104	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0077	PCT	Italy	EP 1 210 104	Validation of EP	EP 1 210 104	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0078	ORO	Japan		2001-621326		07-Sep-2000	07-Sep-2020	AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0066	2 DIV	Japan		2010-166933	2011-066460	22-Sep-2010	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066	PCT	United Kingdom	EP 1 210 104	Validation of EP		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0067	PCT	Canada	2346001	2346001	2346001	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067	PCT	EPC		98850105.9	EP 1 117 354	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067	2 DIV	EPC		10179341.2	EP 2 286 542	24-Sep-2010	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067	DIV	Japan		2008-227248	2009-019066	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0068	PCT	Canada	2385782	2385782	2385782	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	PCT	EPC	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	EPC	France	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	EPC	Germany	60019774.3	970579.9	1217993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	EPC	Italy	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	PCT	Japan	42840324	2001-529425		05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	2 DIV	Japan		2008-135738		05-Jun-2008	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068	EPC	United Kingdom	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0069	PCT	Canada	2395195	2395195	2395195	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	EPC	EP 1 185 371	937892.9	EP 1 185 371	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	France	EP 1 185 371	937892.9	EP 1 185 371	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	Germany	60012620	Validation of EP		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	Ireland	EP 1 185 371	937892.9	EP 1 185 371	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	Italy	EP 1 185 371	937892.9	EP 1 185 371	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	Japan	4166807	2000-021075		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069	PCT	United Kingdom	EP 1 185 371	Validation of EP		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0070	PCT	Canada	2400848	2400848	2400848	16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070	PCT	EPC	EP 1 282 398	1927497.4	EP 1 282 398	16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070	PCT	France	EP 1 282 398	1927497.4	EP 1 282 398	16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070	PCT	Germany	60121570	Validation of EP		16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070	PCT	Italy	EP 1 282 398	1927497.4	EP 1 282 398	16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070	PCT	Japan	2001-583733	Validation of EP		16-May-2001	16-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0070	2	Div	Japan		2010-257452		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070		PCT	United Kingdom		Validation of EP		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING DOSAGE FORM SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Austria	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Belgium	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		PCT	Canada	2416109	2416109	2416109	04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Cyprus, Republic of	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Denmark	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		PCT	EPC	EP 1318 788	1975724.4	EP 1 318 788	04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Finland	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	France	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Germany	60131991	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Greece	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Ireland	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Italy	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 3 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0071		PCT	Japan	4400277	2010-526199		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Liechtenstein	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Luxembourg	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Monaco	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Netherlands	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Portugal	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Spain	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Sweden	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Switzerland	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	Turkey	200801690	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071		EPP	United Kingdom	EP 1 318 786	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0072		EPC	Belgium	EP 1 341 521	EP 1 341 521		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0072	PCT	PCT	Canada		2428785	2428785	16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
03.0072	PCT	PCT	EPC	EP 1 341 521	1274072.6	EP 1 341 521	16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	France	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	EPC	EPC	Germany	80137362.6	60137362.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	Ireland	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	Italy	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	Japan	4511647	2002-590594		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	Liechtenstein	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	EPP	EPP	Spain	ES 3317874 T3	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	EPC	EPC	Switzerland	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072	PCT	PCT	United Kingdom	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0077	PCT	PCT	Austria	453454	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Belgium	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Canada	2408696	2408696	2408696	26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Cyprus, Republic of	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Denmark	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	EPC	EP 1 313 564	1930812.1		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Finland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	France	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Germany	60140947	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Greece	3071059	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077	PCT	PCT	Ireland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING

Asses Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0071		EPC	Italy	N.2.1976BE02	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0072		PCT	Japan	4343476	2001-551963		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0073		PCT	Liechtenstein	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0074		PCT	Luxembourg	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0075		PCT	Monaco	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0076		PCT	Netherlands	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077		PCT	Portugal	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0078		PCT	Spain	2334435	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0079		PCT	Sweden	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0080		PCT	Switzerland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0081		PCT	Turkey	TR 2010	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0082		PCT	United Kingdom	0698574	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0083		EPC	Austria	EP 1 429 731	EP Validation		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0084		EPC	Belgium	EP 1 429 731	EP 1 429 731		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0085		PCT	Canada	EP 1 429 731	2460867	2460867	19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0086		EPC	Cyprus, Republic of	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0087		ORD	Denmark	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0088		ORD	Finland	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0089		ORD	France	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0090		ORD	Germany	60217367.1			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0091		ORD	Greece	20070402853			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0092		ORD	Ireland	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0093		ORD	Italy	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0094		ORD	Japan	4444129	2003-528522		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0095		ORD	Luxembourg	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0096		ORD	Monaco	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0097		ORD	Netherlands	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0098		ORD	Portugal	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0099		ORD	Spain	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0100		ORD	Sweden	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0101		EPC	Switzerland	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0102		ORD	United Kingdom	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0103		EPP	Austria	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0104		EPP	Belgium	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0105		PCT	Canada	2448480	2448480		31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0106		EPP	Cyprus, Republic of	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0107		EPP	Denmark	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0108		PCT	EPC	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0109		EPP	Finland	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0110		EPP	France	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0111		EPP	Germany	EP 1 392 441			31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS

Asset Transfer Agreement (EPH) to EDI Pharms Holdings) - 2 August 2011
 Schedule 2. Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0078	EPP	EPP	Greece	20090402576	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Ireland	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0078	EPP	EPP	Italy	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	PCT	PCT	Japan	4323380	2805-601597		31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Liechtenstein	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Luxembourg	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Mexico	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Netherlands	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Portugal	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Spain	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Sweden	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Switzerland	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	Turkey	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079	EPP	EPP	United Kingdom	EP 1 382 441	2739588.8	EP 1 382 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0080	DRV	DRV	EPC		7011731.2	EP 1 820 530	16-Jun-2007	13-Sep-2022	INTO NANOPARTICULATE FORM NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Austria	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Belgium	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Bulgaria	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Canada		2475082	2475082	04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Czech Republic	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Denmark	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	EPC	EP 1 471 887	3737537.5	EP 1 471 887	04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Finland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	France	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Germany	80332212	60332312.3	EP 1 471 887	04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Greece	3072191	03 737 537.5-1219	EP 1 471 887	04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Hungary	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Ireland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME
03.0083	PCT	PCT	Italy	EP 1 471 887	IT 364228E/2010		04-Feb-2003	04-Feb-2023	AS A SURFACE STABILIZER NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME

Asset Transfer Agreement (EPVIL to EDY Pharma Holdings) - 2 August 2013
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filings Date	Normal Expiry Date	Short Title / Subject Matter
03.0083	PCT	PCT	Japan	4556359	2003-063445	Patent Pub Date	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Liechtenstein	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Netherlands	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Portugal	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Slovakia	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Spain	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Sweden	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	Switzerland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083	PCT	PCT	United Kingdom	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0084	PCT	PCT	EPC	EP 1 401 401	1401401		24-Jun-2002	24-Jun-2022	METHOD FOR HIGH THROUGH PUT SCREENING USING A SMALL SCALE MILL OR MICROFLUIDICS
03.0084	PCT	PCT	France	EP 1 401 401			24-Jun-2002	24-Jun-2022	METHOD FOR HIGH THROUGH PUT SCREENING USING A SMALL SCALE MILL OR MICROFLUIDICS
03.0084	PCT	PCT	Italy	EP 1 401 401	3756105		24-Jun-2002	24-Jun-2022	METHOD FOR HIGH THROUGH PUT SCREENING USING A SMALL SCALE MILL OR MICROFLUIDICS
03.0086	EPP	EPP	Belgium	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	PCT	PCT	Canada		2479737	2479737	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	PCT	PCT	EPC	EP 1 490 025	3723782.3	EP 1 490 025	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	France	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	Germany	60319073.1	3723782.3	DE 603 19 073 12	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	Hungary	E003331	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	Ireland	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	Italy	2401755200 B	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	PCT	PCT	Japan	4611641	2003-377954		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086	EPP	EPP	Liechtenstein	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0086		EPP	Spain	EP 1 480 025	3723782.3		20-Mar-2003	20-Mar-2023	MANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086		EPP	Switzerland	EP 1 480 025	3723782.3		20-Mar-2003	20-Mar-2023	MANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086		EPP	United Kingdom	EP 1 480 025	3723782.3		20-Mar-2003	20-Mar-2023	MANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0087		PCT	Canada		2478735	3478735	20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087		PCT	EPC		3718910.6	EP 1 487 419	20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087		PCT	Japan		2006-577863		20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087	2	DIV	Japan		2010-176286		20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0088		EPC	Belgium	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		PCT	Canada		2472582	2472582	31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		PCT	EPC	EP 1 478 342	2806274.3	EP 1 478 342	31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	France	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	Germany	60235411	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	Ireland	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	Italy	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		PCT	Japan	4623966	2003-877552		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	Liechtenstein	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088		EPC	Spain	EP 1 478 342	ES 1 478 342		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER

Asset Transfer Agreement (EPIL to EDY Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDY Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0088	EPC	EPC	Switzerland	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088	EPC	EPC	United Kingdom	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0089	EPP	EPP	Austria	E 487470	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Belgium	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Bulgaria	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	PCT	PCT	Canada		2498207	2498207	11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Cyprus, Republic of	CY201011010	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Czech Republic	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Denmark	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	PCT	PCT	EPC	EP 1 553 927	3616399.6	EP 1 553 927	11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Estonia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Finland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	France	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Germany	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Greece	3072488	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Hungary	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Ireland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Italy	N.2005148E/20 11	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	PCT	PCT	Japan		2005-503259		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Liechtenstein	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP	EPP	Luxembourg	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS

Asset Transfer Agreement (EPL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0089	EPP		Monaco	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Netherlands	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Portugal	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Romania	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Slovakia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Slovenia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Spain	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Sweden	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Switzerland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		Turkey	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089	EPP		United Kingdom	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0091	ARZ	ORD	Argentina		90100919		13-Mar-2009	13-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	AU2	ORD	Australia		2008-238108		27-Aug-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		ORD	Canada		2479665	2479665	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	CA2	ORD	Canada		2718189		03-Sep-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		ORD	EPC		3722781.5	EP 1 490 030	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		EPP	France		3723761.5		30-Mar-2003	30-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		EPP	Germany		EP 1 490 030	EP 1 490 030	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		EPP	Ireland		3723781.5		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	IL2	ORD	Israel		207893		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		EPP	Italy		EP 1 490 030	EP 1 490 030	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091		ORD	Japan		2003-577857		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Ascet Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0091	2	DIV	Japan		2009-266999		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	JP2	ORD	Japan		2010-550866		10-Sep-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	KR2	ORD	Korea, Republic of		10-2010-7021510		12-Mar-2009	12-Mar-2028	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	MX2	ORD	Mexico		MX/09/2010/036666		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	NZ2	ORD	New Zealand		587658		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	PK2	ORD	Pakistan		2292009		13-Mar-2009	13-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	WO2	ORD	PCT		PCT/US2009/036965	WO/2009/114895 A1	12-Mar-2009	12-Mar-2013	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	SG2	ORD	Singapore		2010-06315-4		31-Aug-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	ZA2	ORD	South Africa		2010/06946		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	EPP	EPP	Switzerland	EP 1 490 030	3723731.5		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	TW2	ORD	Taiwan		98106213	200942272	13-Mar-2008	13-Mar-2028	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091	EPP	EPP	United Kingdom	EP 1 490 030	EP 1 490 030		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0092	2	PCT	Australia		2006262144		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Brazil		PI0612665-0		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Canada		2481390	2481390	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092	2	PCT	Canada		2813466		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	China (People's Republic of)		Z006901004		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	ORD	EPC		3723991	EP 1 494 040	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092	DIV	DIV	EPC		10010239.5		27-Sep-2010	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092	2	PCT	Eurasian Patent Organization		200800090		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Israel		195222		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Japan		2005-563377		14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092	2	DIV	Japan		2010-140607	2010-246220	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092	2	PCT	Japan		2008-518366		23-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Korea, Republic of		2008-7081853		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Mexico		MX/A/2009/000366		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Norway		20080403		25-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	Singapore		200718865-3		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	SG2DI	DIV	Singapore		201003704-6		29-Dec-2010	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092	2	PCT	South Africa	2008000376	2008-30376		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS

Asset Transfer Agreement (EPII to EBT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Class	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0093	2	ORD	Argentina		80101116		27-Mar-2009		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0155		PCT	Canada	2457064	2457064	2467064	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	PCT	Canada		2719811	2719811	27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093		PCT	EPC		3602953	EP 1 519 715	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	PCT	EPC		5726084.8	EP 2 371 316	27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	3	PCT	Japan	4395074	2004-549866		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	3	DIV	Japan		2009-199576	2010-013462	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	3	PCT	Japan		2011-503285		24-Sep-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	PCT	Pakistan		2492309		19-Mar-2009	19-Mar-2024	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	PCT	Pakistan		PCT/US2009/039480		27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	ORD	Taiwan		5511457		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	ORD	Taiwan		98109759		25-Mar-2009	25-Mar-2029	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	ORD	Taiwan		00581-2009	201006466	20-Mar-2009	25-Mar-2029	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093	2	ORD	Venezuela		40566		20-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Algeria	3809	30107837		26-May-2004	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Argentina		300401596		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Armenia	12642	2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	PCT	Armenia		2003301507		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Australia	3093301807	2005564174		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	DIV	Australia		200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Azerbaijan	12642	2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Azerbaijan		200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Belarus	12642	2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Belarus		P10311275-6		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Brazil		1081-2003		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Chile		381270.A		23-May-2003	19-May-2022	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	China (People's Republic)		20101044539.8	CN 101787233A	18-Mar-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	DIV	China (People's Republic)		20101044539.8	CN 101787233A	18-Mar-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	4	DIV	China (People's Republic)		20101044539.8	CN 101787233A	18-Mar-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Eurasian Patent Organization	12642	200401596		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	DIV	Eurasian Patent Organization		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Hong Kong		5108746.5		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	DIV	RON	Hong Kong		11109469.9		18-Jan-2011	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	DIV3	RON	Hong Kong		11109470.8		18-Jan-2011	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Hong Kong		11108061.8		14-Jun-2011	27-Mar-2029	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Hong Kong		38432804		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	India		WB0200402838		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Indonesia		165332		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Israel		200401596		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Kazakhstan	12642	2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Kazakhstan		2004-7019041		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Korea, Republic of		200401596		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Kyrgyz Republic		200401596		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0093FR	3	EUC	Kyrgyz Republic		2009-00486		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Malaysia		PL-2003-1529		23-May-2003	24-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Mexico	252667	2004081693		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Moldova	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Moldova		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Marocco	27250	27954	27250	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	New Zealand	537324	537324		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Norway		20050224		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Philippines	1-2004-	1-2004-501815		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	Div	Div	Philippines	501815	1-2008-502769		12-Dec-2008	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Russian Federation	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Russian Federation		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Singapore	108045	200405076-6	108045	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	Div	Singapore		200705056-6	159391	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	South Africa	200410308	200410308		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Tajikistan	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Tajikistan		3008-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Thailand		83589		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Tunisia	18880	SN04-230		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		EUC	Turkmenistan	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR	2	EUC	Turkmenistan		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Uruguay		27282		26-May-2003	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		ORD	Venezuela		0535-2003		26-May-2003	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR		PCT	Viet Nam	8383	1-2004-01371		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0095		PCT	EPC	EP 1 503 737	3728678.8	EP 1 503 737	05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	France	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	Germany	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	Ireland	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	Liechtenstein	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	Switzerland	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0095		EPP	United Kingdom	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	STATIN COMBINATIONS
03.0096		PCT	Canada		2488488	2488488	10-Jun-2003	10-Jun-2023	STATIN COMBINATIONS
03.0096		PCT	EPC		3735952.5	EP 1 501 789	10-Jun-2003	10-Jun-2023	STATIN COMBINATIONS
03.0096		PCT	Japan		2004-510760		10-Jun-2003	10-Jun-2023	STATIN COMBINATIONS
03.0096		PCT	Japan		2004-510752		10-Jun-2003	10-Jun-2023	STATIN COMBINATIONS
03.0098		PCT	Japan	4533134			10-Jun-2003	10-Jun-2023	NANOPARTICULATE POLYCYCLOANOL FORMULATIONS AND NOVEL POLYCYCLOANOL COMBINATIONS
03.0098		PCT	Belgium	EP 1 617 816	4785761	4785761	08-Jun-2009	24-Feb-2024	NOVEL POLYCYCLOANOL FORMULATIONS
03.0098		PCT	Canada		2517679	2517679	24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0098		PCT	EPC	EP 1 617 816	4785761	EP 1 617 816	08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0098	3	Div	EPC	EP 1 617 816	8006485.2	8006485.2	08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2017
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0099		PCT	France	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Germany	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Hungary	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Ireland	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Italy	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Japan	EP 1 617 816	2036-532300		24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099	2	DW	Japan		2010-233665		24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		DW	Japan		2011-148037		04-Jul-2011	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Liechtenstein	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Spain	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	Switzerland	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099		PCT	United Kingdom	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0100		PCT	Canada		2504610	2504610	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	EPC		3811280.3	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Belgium		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	France		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Germany		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Hungary		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Ireland		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Italy		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Spain		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Switzerland / Liechtenstein		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	United Kingdom		EP Validation	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0100		PCT	Japan		2004-552054		12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIABLE AND COMPRISING PULLULAN
03.0102		PCT	Canada		2492459	2492459	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102		PCT	EPC		3764723.7	EP 1 551 457	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102	3	DW	EPC		10010944.5	EP 2 583 864	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102		PCT	Japan		2004-521891		16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS

Asset Transfer Agreement (EPFL to EDY Pharma Holdings) - 2 August 2011
Schedule 2. Patents

EST Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0103		PCT	Canada		2500908		04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0103		PCT	EPC		3749342.8	EP 1 558 091	04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0103		PCT	Japan		2004-543281		04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0106		PCT	Canada	2513084	2513084	2513084	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0106		PCT	EPC		4706953.9	EP 1 557 499	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0106		ORD	Japan	4463846	2004-506639		30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0108		PCT	Canada		2508201	2508201	23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108		PCT	EPC		3724136.5	EP 1 613 276	23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108	3	DIV	EPC		19011287.7	EP 2 263 851	28-Sep-2010	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108		PCT	Japan		2004-570751		23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108		DIV	Japan		2011-66632		23-Jul-2011	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108		PCT	Canada		2523035	2523035	24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0108		PCT	EPC		47511768.6	EP 1 626 742	24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0108		PCT	Japan		2006-532908		24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0110		PCT	Canada		2533183	2533183	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	EPC		4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	France		4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	Germany		6.02004E+11	DE 60 3004 012 117	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	Ireland		4786037.4	EP 1 656 063	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	Italy		4786037.4	EP 1 658 063	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	Japan		2006-521039	2006-521039	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	Spain		4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110		PCT	United Kingdom		4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0111		PCT	Belgium		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Canada		2534324		26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	EPC		4776615.9	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	France		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Germany		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Hungary		EP05149	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Ireland		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Italy		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Japan		2006-523181		26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111		PCT	Liechtenstein		EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0111.		PCT	Spain	ES 2318330	EP Validation	EP 1 651 189	25-Jun-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Switzerland	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	United Kingdom	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0112.		PCT	Canada	2544404	2544404		31-Oct-2003	31-Oct-2023	NANOPARTICULATE NIMESULIDE COMPOSITIONS
03.0112.		PCT	Japan	2005-510942	2005-510942		31-Oct-2003	31-Oct-2023	NANOPARTICULATE NIMESULIDE COMPOSITIONS
03.0121.		PCT	Belgium	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Canada	2544527	2544527		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	EPC	4810301.6	4810301.6		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	France	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Germany	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Hungary	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Ireland	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Italy	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Japan	3306-538688	3306-538688		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Liechtenstein	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Spain	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	Switzerland	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.		PCT	United Kingdom	EP Validation	EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0122.		PCT	Canada	2548356	2548356		09-Nov-2004	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETED NANOPARTICULATE ACTIVE AGENT DELIVERY
03.0122.		PCT	EPC	4810355.5	4810355.5	EP 1 659 442	09-Nov-2004	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING
03.0122.		DIV	EPC	11172198.1	11172198.1		30-Jun-2011	09-Nov-2024	NANOPARTICULATE ACTIVE AGENT DELIVERY COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING
03.0122.		PCT	Japan	2005-538772	2005-538772		09-Nov-2004	09-Nov-2024	NANOPARTICULATE ACTIVE AGENT DELIVERY COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING

Asset Transfer Agreement (EPH to EDY Pharma Holdings) - 3 August 2011
 Schedule 2: Patents

EDY Ref	Sub Case Type	Case Type	Country	Parent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0123	PCT	PCT	Australia		2005307787		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Brazil		PI0518187-9		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Canada		2587710		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	China (People's Republic)		2005-01046919.5	CN101106972A	16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	EPC		5851781.2		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	ORD	ORD	Hong Kong		6102504.7		30-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Japan		2007-54145A		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Korea, Republic of		2007-703288		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Mexico		MX/A/2007/035885		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Norway	132306	28073085		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	Singapore		200703464-S		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123	PCT	PCT	South Africa		200763915		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0124	PCT	PCT	Australia		2005311731		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Brazil		PI0518172-9		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Canada		2553923		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	China (People's Republic)		2005000415	101365449	02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Egypt		PC/TNA/524/2007		31-May-2007	31-May-2027	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	EPC		5852820.9		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Eurasian Patent Organization		200701202		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	ORD	ORD	Hong Kong		8102505.9		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	India		2154903 NP/2007		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Indonesia		W00000701693		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Israel		183549		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Japan		2007-544559		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Korea, Republic of	278727	2007-7014839		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Mexico	556009	MX/A/2007/035539		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	New Zealand		20073334		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Norway		200704011-6		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Singapore	132897	200704528		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	South Africa	200704528			02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124	PCT	PCT	Ukraine	89513	200707397		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Start Title / Subject Matter
03.0124	PCT	PCT	United Arab Emirates		47322007		02-Dec-2006	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0125	PCT	PCT	Canada		2631767		04-Dec-2006		NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0126	PCT	PCT	EPC		9844719.2		04-Dec-2006		NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0125	PCT	PCT	Japan		2008-543494		04-Dec-2006	04-Dec-2026	NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0132	PCT	PCT	Canada		2601363		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	China (People's Republic of)		200680017368.X		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	EPC		6744332.9		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	ORD	ORD	Hong Kong		8166808.1		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	Israel		165963		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	Mexico		MX/A/2007/011495		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	New Zealand		561666		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	Nigeria		NG/02/0098719		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	Norway		20075234		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	Singapore		200708549-1		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	South Africa		2007086457		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	United Arab Emirates		6572307		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132	PCT	PCT	EPC		6738842.1		18-Mar-2006	16-Mar-2026	NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/OPTICALLY ACTIVE FORMULATIONS
03.0134	PCT	PCT	Australia		2006227623		18-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Brazil		P10605282-2		16-Mar-2008	18-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Canada		2601812		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	EPC		6738555.9		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	ORD	ORD	Hong Kong		81070754	1116430	16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Israel		165952		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Japan		3008-602038		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Korea, Republic of		2007-7023749		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Mexico		MX/A/2007/011494		17-Sep-2007	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	Norway		20075235		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134	PCT	PCT	South Africa		2007086458		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS

Assat Transfer Agreement (EPL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0135	PCT	PCT	Australia		2006226987		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Brazil		P18659700-9		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Canada		2602341		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	EPC		6738359.5		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Eurasian Patent Organization		260703048		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	POX	POX	Hong Kong		9167065.7		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Israel		186159		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Japan		2006-503175	2008-584609	23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Korea, Republic of		2007-7034129		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Mexico		MX/a/2007/011772		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Norway		20075366		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	Singapore	195679	200709475-9		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135	PCT	PCT	South Africa	2007708544	2007708544		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0137	PCT	PCT	Australia		2006235487		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	Brazil		P10807537-1		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	Canada		2604735	2604735	12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	China (People's Republic)		200680321016.4		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	EPC		6740896.3	EP 1 871 345	12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	Eurasian Patent Organization	14611	200702214		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	POX	POX	Hong Kong		6167271.7		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	India		3956/KOLNP/2007		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	PCT	Israel		186609		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0137	PCT	Japan		2008-506632		12-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	Korea, Republic of		2007-7025883		13-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	Mexico		MX/A/2007/012778		13-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	Norway		20075774		12-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	Singapore	136501	200716779-4		12-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137	PCT	South Africa	200706702	200706702		12-Apr-2008	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0147	PCT	South Africa	200710113	200710113		08-May-2008	08-May-2026	NANOPARTICULATE CLOPIDOGREL FORMULATIONS GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151	PCT	Canada		2080106		04-Sep-2008	30-Mar-2026	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151	PCT	EPC		8732593.2	EP 2 159 470	20-Oct-2008	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151	PCX	Hong Kong		10106443.8		03-Jul-2010	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151	PCT	Japan		2008-554748	2010-522207	10-Sep-2008	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151	ORD	PCT		PCT/US2008/067701	WO/2008/118754 A3	20-Mar-2008		GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0152	PCT	Australia		2007221471		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	ORO	Brazil		P10703043-2		08-Feb-2007	08-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Canada		2643492		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	China (People's Republic of)		200780012936.5		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	EPC		7750335.8		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCX	Hong Kong		8110368.4	1132903A	06-Nov-2009	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	India		3475R/OL/MP/2008		08-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Israel		193892		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Japan		3008-557272		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Korea, Republic of			WO/2007/100466	08-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Mexico			WO/2007/100466	09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	New Zealand		570676		08-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	Singapore		747489		08-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152	PCT	South Africa	2008/07397	2008/07397		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	Australia		2007210190		24-Jan-2007	24-Jan-2027	

Asset Transfer Agreement (EPL to EDI Pharma Holdings) - 2 August 2017
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0153	PCT	PCT	Brazil		P19707514-3		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Canada		2640444		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	China (People's Republic)		200700010847.6	101443018	24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	EPC		7716966.2		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Hong Kong		9110975.9	1153162A	24-Nov-2009	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Israel		193079		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Japan		2008-552475		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Korea, Republic of		2008-7028792		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Mexico		MX/A/2008/039725		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	New Zealand		570604		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	Singapore	144645	496763		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153	PCT	PCT	South Africa	2008/06758	2008/06758		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0154	PCT	PCT	Armenia	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Australia	2005315473	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Azerbaijan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Belarus	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Brazil		P06-190888.6		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Canada		2593675		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	China (People's Republic)		200501047594.9		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	EPC		5684300	EP 1 835 869	15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Eurasian Patent Organization	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Hong Kong		9103316.3		25-Mar-2009	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	India		2407KOLM72007		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Israel		183945		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Japan		2007-246924		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Kazakhstan		200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Korea, Republic of		2007-7015963		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Kyrgyz Republic		200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Mexico		MX/A/2007/007342		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Moldova		200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154	PCT	PCT	Norway		20073569		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0154		PCT	Russian Federation	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS INJECTABLE FORMULATIONS OF NANOPARTICULATE TACROLIMUS
03.0154	2	DM	Singapore		334624	161203	12-Mar-2010	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154		PCT	South Africa	13741	2007-05213		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154		PCT	Tajikistan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154		PCT	Turkmenistan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154		PCT	Turkmenistan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0156		PCT	Australia		2006210640		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Brazil		P10098173-8		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Canada		2599441		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	China (People's Republic)		302880012670.9	CN 101180118A	16-Oct-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	EPC		6735983.6		17-Sep-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Eurasian Patent Organization		200701793		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Hong Kong		6104666.7		08-Oct-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Israel		105292		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Japan		2007-557184		24-Aug-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		ORD	Korea, Republic of		70219192007		21-Sep-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Mexico		MX/a/2007/010394		24-Aug-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Norway		20074059		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	Singapore		200706247-4		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0156		PCT	South Africa	200706783	200706783		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCE TAXEL AND ANALOGUES THEREOF
03.0157		PCT	Armenia	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157		PCT	Australia		2006214443		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157		DM	Australia		ibc		ibc		AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157		PCT	Azerbaijan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157		PCT	Belarus	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0157.		PCT	Brazil		P10608087-1		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Canada		2567716		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	China (People's Republic)		20068002468.6		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	EPC		6735067.8		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.	2	DIV	EPC		11001512		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.	DIV2	DIV	EPC		11001511		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE (CLOSAZAM) AND MIDAZOLAM
03.0157.		PCT	Eurasian Patent Organization	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		ORD	Hong Kong		8105286.4		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Israel		195265		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Japan		2007-585648		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Kazakhstan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Korea, Republic of		2007-7020820		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Kyrgyz Republic	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Mexico		MX/42967002915		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Moldova	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Norway		20074602		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Russian Federation	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Singapore		200705897-7		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	South Africa	200707610	200707610		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Tajikistan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Turkmenistan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Armenia		200703638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref.	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0167	PCT		Australia		2006310206		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Azerbaijan		200702636		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Belarus		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Canada		2610480	2610480	05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		China (People's Republic)		200690228919		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		EPC		6844132.8	EP 1 901 726	05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Eurasian Patent Organization		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Israel		167942		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Japan		2006-514948		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Kazakhstan		200702636		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Korea, Republic of		2007-7039860		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Kyrgyz Republic		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Mexico		MX/A/2007/015304		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Moldova		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Norway		20076892		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Russian Federation		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Singapore	137966	200718249.9		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		South Africa	200710764	200710764		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Tajikistan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167	PCT		Turkmenistan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0168	PCT		Australia		2006253177		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT		Austria		6772091.2		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC		Belgium	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT		Canada		2610448	2610448	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT		China (People's Republic)		2006-5026329.2	101232870	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT		EPC	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT		Eurasian Patent Organization		200702641		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	2	EW	Eurasian Patent Organization		201100022		13-Jun-2011	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC		France	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC		Germany	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCK		Hong Kong	HK1116487	8110082.8	1118487	10-Sep-2008	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS

Asset Transfer Agreement (EPIL to ECI Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0168	EPC	Hungary	EP 1 895 964	8772091.2	1895994	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC	Ireland	EP 1 895 964	8772091.2	EP 1 895 964	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT	Israel		187841		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0166	EPC	Italy	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0166	PCT	Japan		2006-514949		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0166	PCT	Korea, Republic of		2007-703987		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC	Liechtenstein		6772091.2		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0166	PCT	Mexico	270494	MX/A/2007/015309		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT	Norway	137987	20076691		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT	Singapore		2007192496		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	PCT	South Africa	200710763	200710763		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0166	EPC	Spain	EP 1 895 984	8772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC	Switzerland	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC	United Kingdom	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168	EPC	Belgium	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	ORD	Canada		2611475	2611475	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	PCT	EPC	EP 1 898 882	6772583.8	EP 1 898 882	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	France	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Germany	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Hungary	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Ireland	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Italy	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	PCT	Japan		2006-50702540719		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Liechtenstein	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Spain	EP 1 898 882	6772583.8	2335506	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	Switzerland	EP 1 898 882	EP Validation		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0168	EPC	United Kingdom	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0171	PCT	Japan		2009-517090		14-Jun-2006	14-Jun-2026	NANOPARTICULATE AZEL MIDIFINE FORMULATIONS
03.0172	ORD	Argentina		70102341	63640	30-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172	ORD	Australia		2007256963		12-Jan-2006	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS

Asset Transfer Agreement (EPH) to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0172		ORD	Canada		2653534		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	EPC		1734043.9	EP 2 040 675	22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Iran (Islamic Republic of)	320003143	386631143		26-May-2007	26-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Israel		185524		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Japan		2009-515980		22-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Korea, Republic of		2009-7031849		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Mexico		MX/A/2003/015275		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	New Zealand		673455		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Pakistan		6063007		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Singapore		200908545.3		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		DW	Singapore		20101417.2		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	South Africa	2008069971	200809971		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Taiwan		96119130		29-May-2007	29-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172		ORD	Venezuela		01142-2007		30-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0174		ORD	Canada		2614412		06-Jul-2006	06-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
03.0174		ORD	Japan		2009-518732		08-Jul-2006	08-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
03.0174		ORD	Japan		2622233		08-Jul-2006	08-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
03.0176		PCT	Canada		6803492.5		13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0176		PCT	EPC		2008-531268		13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0176		PCT	Japan		2008-531268		13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0177		PCT	Canada		3622758		13-Sep-2006	13-Sep-2026	ARIPRAZOLE INJECTABLE FORMULATIONS OF NANOPARTICULATE
03.0177		PCT	EPC		6814574.7		13-Sep-2006	13-Sep-2026	ARIPRAZOLE INJECTABLE FORMULATIONS OF NANOPARTICULATE
03.0177	2	DW	EPC		10010436.2	EP 2 279 727	30-Sep-2010	30-Sep-2026	ARIPRAZOLE INJECTABLE FORMULATIONS OF NANOPARTICULATE
03.0177		PCT	Japan		2008-531289		13-Sep-2006	13-Sep-2026	ARIPRAZOLE INJECTABLE FORMULATIONS OF NANOPARTICULATE
03.0178		ORD	Australia		2007257887		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178		ORD	Canada		2654909		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178		ORD	EPC		7798449		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178		ORD	Japan		2009-515507		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178		ORD	Korea, Republic of		2009-7000297	09-16864	07-Jan-2009	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178		ORD	Taiwan		96121317		13-Jun-2007	13-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0180		PCT	Canada		2857379		09-Jan-2009	09-Jul-2027	TOSYLATE NANOPARTICULATE FORMULATIONS OF SORAFENIB
03.0180		PCT	EPC		7799416.4		10-Feb-2009	03-Jul-2027	NANOPARTICULATE FORMULATIONS OF SORAFENIB
03.0180		PCT	Japan		2009-515919		09-Jan-2009	09-Jul-2027	TOSYLATE NANOPARTICULATE FORMULATIONS OF SORAFENIB
03.2004		ORD	Argentina		PO63102028		17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004		ORD	China (People's Republic)		2005-80523798.1	Published	17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND

Asset Transfer Agreement (EPL to EDY Pharma Holdings) - 3 August 2011
 Schedule 2: Patents

EDY Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.2004.		ORD	EPC		577928.4	EP 1 773 335	17-May-2006	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Hong Kong		9109880.7		17-May-2006	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	India		0665870E/INP/2006		17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Japan		2007-527369	3008-506982	17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Malaysia		P/20052114		11-May-2005	11-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Malta		2778		18-May-2005	18-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Norway		20065737		17-May-2005		NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2007.		PCT	EPC		8850115.1	EP 2 230 908	03-Jun-2010		NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2007.		ORD	PCT		PCT/US2008/086842	WO/2009/076620	12-Dec-2008		NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2013.		ORD	PCT		PCT/US2010/036304	WO/2010/138881	27-May-2010	27-May-2014	NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2021.		ORD	Canada		2723988		19-Nov-2010		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		PCT	EPC		9763482.A		07-Jan-2011		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		ORD	Japan		3011-513648		10-Dec-2010		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		ORD	PCT		PCT/US2009/046806	WO/2009/152192	10-Jan-2009		COMBINATION OF A TRIPTAN AND AN NSAID
03.2033.		PCT	PCT		PCT/US2011/036949		16-May-2011	18/05/2015	NANOPARTICULATE CINACALCET COMPOSITIONS CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.		ORD	Canada		2627948		26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.	2	ORD	Canada		2627951		26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.		ORD	EPC		6826636	EP 1 948 135	26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.	2	ORD	EPC		6826637.B	EP 1 951 310	26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1008.		PCT	Australia		2006209212		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Brazil		P/0606532-0		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Canada		2505885		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 3 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1008.	PCT	EPC		8719564.4		26-Jan-2008	31-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Eurasian Patent Organization		200701991		24-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCX	Hong Kong		8104561.3		24-Apr-2008	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	India		3009KOLNP/2007		17-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Israel		1849789		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Japan		2007-553203	2008-528657	26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Mexico		MX/02007/008985		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Norway		20074313		23-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	Singapore	134450	2007036445-5		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.	PCT	South Africa	2007060168	2007060168		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1012.	PCT	Australia		20060354483		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	Canada		2602268		25-Sep-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	China (People's Republic)		200680016440.8		13-Nov-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	EPC		6749871.7	EP 1 668 583	12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCX	Hong Kong		8100361.6		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	Israel		186871		02-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	Japan		2008-506630	2008-535922	12-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.	PCT	Korea, Republic of		70362542007		12-Nov-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Number	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1064.	ORD	EP 1 131 344	Belgium	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Cyprus, Republic of	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	EPC	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	France	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Germany	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Ireland	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Italy	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Liechtenstein	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Luxembourg	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Monaco	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	Switzerland	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.	ORD	EP 1 131 344	United Kingdom	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1065.	PCT	2386231	Canada	2386231	2386231		27-Sep-2003	27-Sep-2020	MEMBRANE TRANSLOCATING PEPTIDE DRUG DELIVERY SYSTEM
04.1068M.	PCT	3726420.7	EPC	EP 1 575 987	3726420.7	EP 1 575 987	21-Apr-2003	21-Apr-2023	CONJUGATES OF MEMBRANE TRANSLOCATING AGENTS AND PHARMACEUTICALLY ACTIVE AGENTS/COMPOUNDS/AGENTS OF TRANSLOCATION MEM
04.1103. 04.1255.	PCT	2009-551241 US 5,641,745	Japan United States	2009-551241 US 5,641,745	09/478,569	2009-551241	09-Nov-2007	09-May-2038 2-Apr-2016	MODIFIED RELEASE LYOXOPROFEN COMPOSITIONS OR BIOERODIBLE MICRO- AND NANOSPHERES CONTAINING

Asset Transfer Agreement (EPH) to EBY Pharma Holdings) - 7 August 2011
 Schedule 2: Patents

EPH Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1806		ORD	Australia	557735	6636181		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Austria	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Belgium	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		ORD	Canada	2054822	2054822		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Denmark	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		ORD	EPC	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	France	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Germany	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Greece	20000409471	3032769	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		ORD	Ireland	82916	3952780		01-Nov-1991	02-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Italy	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Luxembourg	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Netherlands	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		ORD	New Zealand	240420	240420		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		ORD	South Africa	916711	916711		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Spain	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Sweden	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	Switzerland	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806		EPC	United Kingdom	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1807			Finland	EP 0 812 256	92923044.9			10-Nov-2012	Passive transdermal device
04.1807			Germany	EP 0 812 256	92923044.9			05-Dec-1997	Passive transdermal device
04.1809		EPC	Austria	E239454	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809		EPC	Belgium	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809		EPC	Denmark	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809		PCT	EPC	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION

Asset Transfer Agreement (EPIL to EDY Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1809.		EPC	Finland	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	France	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Germany	69721945.7	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Greece	3045163	20039402960	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Ireland	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Italy	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		PCT	Japan	4335513	2000-516654	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Liechtenstein	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Luxembourg	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Morocco	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Netherlands	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Portugal	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		ORD	South Africa	9879463	9899483	EP 1 023 051	19-Oct-1995	16-Oct-2019	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Spain	E5219837873	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Sweden	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Switzerland	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		ORD	Taiwan	172439	87117880	520298	26-Oct-1996	26-Oct-2018	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	United Kingdom	EP 1 023 051	97947948.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809K.		PCT	Canada	2305353	2305353	2305353	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809K.	3	DIV	Canada	2556783	2556783	2305353	21-Sep-2006		ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1816E.	DIV2	DIV	Australia	2005247019	2005247019		22-Dec-2005	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.	DIV3	DIV	Australia	2307209487	2307209487		28-Jun-2007	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.	DIV4	DIV	Australia	2009201786	2009201786		05-May-2009	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.		PCT	Austria	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Belgium	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Canada	2348871	2348871	2348871	04-Feb-2009	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		DIV	Canada	3655869	3655869		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Cyprus, Republic of	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Denmark	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	EPC	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	2	DIV	EPC	8013053.7	8013053.7		29-Sep-2010	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	3	DIV	EPC	19192522.2	19192522.2		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Finland	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	France	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Germany	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Greece	3067590	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Ireland	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	DIV2	DIV	Israel	211075	211075		03-Feb-2011	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.		PCT	Italy	EP 1 126 826	1915635E2D09		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Japan	4613275	2000-578194		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1816E	2	DM	Japan	EP 1 126 826	2010-156997		09-Jul-2010	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Liechtenstein	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Luxembourg	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Monaco	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Netherlands	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Portugal	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Spain	EP 1 126 826	ES 2013197 T3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Sweden	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	Switzerland	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E		PCT	United Kingdom	EP 1 126 826	99956922.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		ORD	Argentina		PG80165538		02-Nov-1999	02-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Australia	770645	1355300		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A	D	DM	Australia	200423078	AU 200423078 B2		01-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Brazil		P1 9814977-0		01-Nov-1998	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		ORD	Chile		2491-99		02-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	China (People's Republic)	ZL 99814002.3	99814002.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		ORD	Colombia		99866009		02-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Czech Republic		P42001-1539		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		ORD	Hong Kong		30103681.7		14-Apr-2003	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Hungary		P0104039		02-Nov-1999	02-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		PCT	Indonesia	100018066	W 2000191174		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		PCT	Israel	142896	142896		01-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A	D	DM	Israel	812832	179379		16-Nov-2006	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Korea, Republic of	812832	70655182301		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816A		ORD	Malaysia	MY122159A	P1 99004719		01-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A		PCT	Mexico	238634	1004381		01-Nov-1999	01-Nov-2019	(METHYLPHENIDATE)
04.1816A	2	DM	Mexico		67878		10-Jul-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION

Asset Transfer Agreement (Etil to E31 Pharms Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1816N		PCT	New Zealand	511442	511442		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Norway		2001-2139		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Pakistan	137141	0918299		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Peru	3680	110639		03-Nov-1999	03-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Philippines	199902721	1-1999-02721		29-Oct-1999	29-Oct-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Poland	NR 305109	P348624		01-Nov-1999	01-Nov-1999	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Russian Federation	2526347	300111887		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Singapore	80486	200109450-4		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Slovakia		PV2001-599		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N	2	DRV	Slovakia		PV 5011-2011		02-Mar-2011	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Taiwan	1-292717	98119049		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N	0	DRV	Taiwan	1-319327	99111114	300630120	31-Mar-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Thailand	53705	9801024094		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Turkey	300102108	011216		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		ORD	Venezuela		1999-002232		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Viet Nam	5916	1-2001-00390		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N		PCT	Czech Republic		PV3001-4618		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1816N		PCT	EPC	EP 1 178 780	925546	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1816N		ERP	Hungary		P0201994		10-May-2000		MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1816N		ORD	Ireland	83094	990406		20-May-1999	20-May-2019	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1819.JZ		PCT	Austria	6387153T1	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Belgium	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Cyprus, Republic of	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Denmark	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	2	DNV	EPC		7009364.9	EP 1 952 111 A1	29-Apr-2007	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Finland	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	France	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Germany	60035579.9	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Greece	20070403016	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	2	DNV	Ireland	EP 1 178 780	925548		20-May-1999	20-May-2019	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Italy	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Liechtenstein	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Luxembourg	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ		EPP	Monaco	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)

Asset Transfer Agreement (EPIL to EDI Pharms Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1819.JZ	EPP	EPP	Netherlands	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	EPP	EPP	Portugal	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	EPP	EPP	Spain	2280027	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	EPP	EPP	Sweden	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	EPP	EPP	Switzerland	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ	EPP	EPP	United Kingdom	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1830	PCT	PCT	Canada	2462737	2462737	2462737	09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	PCT	PCT	EPC	EP 1 436 610	2779792.7	EP 1 436 610	09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	EPP	EPP	France	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	EPP	EPP	Germany	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	EPP	EPP	Ireland	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	EPP	EPP	Italy	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	PCT	PCT	Japan	4521188	2003-639745		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1830	EPP	EPP	Spain	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1820.	2	ORD	United Kingdom	EP 1 436 610	2776752.7		08-Oct-2003	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM
04.1802.	2	PCT	Canada		2611838	2611838	09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
04.1802.	2	PCT	EPC		677277.6	EP 1 810 718	09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
04.1802.	2	PCT	Japan		2008-516957		09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
05.0082.US	2	ORD	USA	6808828	10366.922	US 2003-0157067 A1	11-Oct-2002	25-Dec-2023	RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
05.0166.US	3	ORD	USA		12467.684		19-Mar-2008	19-Mar-2029	COMPOSITIONS FOR SITE SPECIFIC DELIVERY OF MATINIB MESYLATE AND METHODS OF USE
05.1010.US	2	ORD	USA		117507.737	US 2006-0221112 A1	08-Dec-2005	08-Dec-2026	TORRAMATE PHARMACEUTICAL COMPOSITION
05.1014.US	2	ORD	USA		11671.377		14-Jan-2008	02-Mar-2028	CONTROLLED RELEASE COMPOSITIONS COMPRISING HETEROCYCLIC AMIDE DERIVATIVE NANOPARTICLES
05.1015.US	2	ORD	USA		11568.888		03-Nov-2008	13-Apr-2028	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAELANDIN DERIVATIVES
05.1101.US	2	ORD	USA		11569.206		18-Nov-2008	09-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2
05.1104.US	2	ORD	USA		11568.825	US 2009-0260400 A1	11-May-2009	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEPHALOSPORIN (VANIN)
05.1166.US	2	ORD	USA		11688.636	US 2009-0237596 A1	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
05.1266.US	2	ORD	USA		08474.161		07-Jun-1995	07-Jun-2015	CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN
05.1901.US	4	CON	USA		11671.276		08-Feb-2007	08-Feb-2027	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFTIOXEN
05.1903.US	3	CON	USA		11672.263	US 2011-0028426 A1	07-Feb-2007		NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
05.1904.US	2	CIP	USA		11479.013	US 2010-0347636 A1	30-Jun-2006	30-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING NILVADIPINE
05.2003.US	2	ORD	USA		12049.046	US 2009-0226754 A1	14-Mar-2008	14-Mar-2028	COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
05.2025.US	2	CIP	USA		11768.154	US 2009-0143025 A1	25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
05.2026.US	2	CIP	USA		11768.169	US 2009-0102121 A1	25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2017
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0062	EPC	EPC	Austria	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Belgium	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Bulgaria	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	PCT	PCT	Canada		2463466	2463486	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Cyprus, Republic of	EP 1 443 912	2800993.4	CY1107810	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Czech Republic	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Denmark	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062	PCT	PCT	EPC	EP 1 443 912	2800993.4	EP 1 443 912	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Estonia	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Finland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	France	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Germany	60323180.9	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Greece	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062	EPC	EPC	Ireland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS

Asset Transfer Agreement (EPH) to EDT Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0062.		EPC	Italy	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		PCT	Japan		2003-533905		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062.	2	DR	Japan		2009-042799	2010-47599	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0062.		EPC	Luxembourg	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Monaco	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Netherlands	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Portugal	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Slovakia	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Spain	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Sweden	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Switzerland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	Turkey	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0062.		EPC	United Kingdom	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0166.		ORD	Australia		2009225719		09-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATHIB MESYLATE AND METHODS OF USE
06.0166.		ORD	Canada		2715402		11-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATHIB MESYLATE AND METHODS OF USE

Asset Transfer Agreement (EPFL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0166		ORD	EPC		5721723.9	EP 2 368 265	30-Oct-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Israel		308176		15-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Japan		2011-503685		17-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Korea, Republic of		7019413/2010		31-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Mexico		MX/a/2010/038848		07-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Norway		20101466		19-Oct-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	PCT		PCT/JS2009/037379		17-Mar-2009		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Singapore		1951168		27-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	South Africa		2010/055530		03-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166		ORD	Taiwan		98102324		20-Mar-2009	20-Mar-2029	COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.1014		PCT	Canada		2336293		02-Mar-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014		PCT	EPC		6736732.6		02-Mar-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014		PCX	Hong Kong		6105661.9		21-May-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014		PCT	Japan		2007-558231		02-Mar-2008	02-Mar-2036	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014	2	DIV	Japan		2009-045163		27-Feb-2009	02-Mar-2036	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1015		PCT	Canada		2604281	2604281	11-Oct-2007	13-Apr-2028	COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015		PCT	EPC		6746978		12-Nov-2007	13-Apr-2028	COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015		ORD	Hong Kong		6110293.5		13-Apr-2006	13-Apr-2036	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015		PCT	Japan		2008-606672		13-Apr-2006	13-Apr-2036	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1101		PCT	Japan		2008-611296		09-Nov-2007	09-May-2028	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2

Asset Transfer Agreement (EPII to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1104.	PCT		Australia		2006344711		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Canada		2609296	2609296	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		China (People's Republic)		2006-00025144.6	CN101287453A	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		EPC		6649761.7	EP 1 915 139	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCX		Hong Kong		8110216.9		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Israel		187431		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Japan		2006-525989		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Mexico		MX06/260770-14363		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Norway		20076455		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		Singapore		200717786-7		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.	PCT		South Africa	200706781	200706781		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1105.	PCT		Australia		20065243445		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		Canada		2611506	2611506	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		China (People's Republic)		20068026985.9		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	ORD		EPC		9851355.5	EP 1 937 219	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1105.	REP		Hong Kong		8113605.2		16-Dec-2008	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		Israel		187567		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		Japan		2008-533328	2008-545808	23-May-2008	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		Mexico		MX/02/2007/014764		23-May-2008	24-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		Norway		20076386		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	2 DIV		Singapore		1953105		24-Aug-2010	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	PCT		South Africa		2007710000		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1901.	PCT		Canada		2612984	2612984	05-Jun-2006	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFITOREN
06.1901.	PCT		EPC		6844139.3	1954253	07-Jun-2006	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFITOREN
06.1901.	PCT		Japan		2008-549464		07-Jun-2008	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFITOREN
06.1903.	PCT		Australia		2038285349		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	PCT		Brazil		P10612297-3		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	PCT		Canada		2613474	2613474	19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	2 DIV		China (People's Republic)		201010308027.1	CN101879140A	21-Jun-2010	19-Jun-2028	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	PCT		EPC		6773467.3	EP 1 901 722	19-Jun-2006	19-Jun-2028	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1903.		PCT	Elusion; Patent Organization		2002000292		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Hong Kong		6116215		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Israel		189383		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Japan		2006-518266		20-Dec-2007	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Korea, Republic of		70013582008		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Mexico		MX/a/2007/016181		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Norway		20078628		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	2	DIV	Singapore		1308447		19-Jun-2010		NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	South Africa		200710715		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.2001.		ORD	Taiwan		96125474		12-Jul-2007	12-Jul-2027	NANOPARTICULATE FORMULATIONS OF MODAFINIL
06.2003.		ORD	Canada		2664986		31-Aug-2008		COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
06.2003.		PCT	EPC		8732366.1	EP 2 137 182			ANALGESIC
06.2003.		ORD	PCT		PCT/US2008/057893	WO/2008/116820 A1	14-Mar-2008		COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
06.2025.		PCT	Australia		2007260621		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.		PCT	Canada		2550640		01-Dec-2006	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.		PCT	EPC		7796011.7		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to ED1 Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

ED1 Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.2025.	PCX		Hong Kong		PCT/US2007/072952		25-Jun-2007	30-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Israel		198085		19-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Japan		2009-516756		22-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Korea, Republic of		7001429/2009		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Mexico		MX/a/2008/016223		16-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Norway		20090158		02-Feb-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		Singapore		1749508		04-Dec-2008		COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT		South Africa		2009/10221		02-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT		Australia		2007300822		23-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT		Canada		2660850		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	ORD		EPC		7784540.2		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	ORD		Israel		198086		18-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT		Japan		2008-816757		22-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT		Korea, Republic of		7001440/2009		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to EDI Pharma Holdings) - 2 August 2011
 Schedule 2: Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
08.2026		PCT	Mexico		MX/a/2008/016115		16-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
08.2028		PCT	Norway		20080119		22-Jan-2009	28-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
08.2036		ORD	Singapore		200805995-3		04-Dec-2008		COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
08.2026		PCT	South Africa	2008/10088	2008/10088		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
07.0601.US	2	CON	USA	5332113	077758.954		10-Sep-1991	26-Sep-2011	CAP ASSEMBLY
07.2008.US	2	ORD	USA		12757.805		08-Apr-2010		DRUG DELIVERY COMPOSITION (NANO OSMOTIC PUMP)
07.2009.US	3	ORD	USA		12757.034		08-Apr-2010		CONTROLLED RELEASE CLEZAPINE COMPOSITIONS
07.2027.US	3	ORD	USA		12709.726	2009-0149479 A1	12-Sep-2008	12-Sep-2028	DOSING REGIMEN
07.2030.US	4	ORD	USA		12387.824		04-Mar-2009	04-Mar-2029	STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
07.2034.US	2	ORD	USA		12788.186	US 2010-0316725 A1	26-May-2010	26-May-2030	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
08.2005		ORD	PCT		PCT/AUS2010/030387		08-Apr-2010		DRUG DELIVERY COMPOSITION
08.2006	2	ORD	PCT		PCT/AUS2010/030393		08-Apr-2010		CONTROLLED RELEASE CLEZAPINE COMPOSITIONS
08.2008		ORD	Taiwan		98111212		09-Apr-2010		DRUG DELIVERY COMPOSITION
08.2005	2	ORD	Taiwan		98111214		09-Apr-2010		CONTROLLED RELEASE CLEZAPINE COMPOSITIONS
08.2027		PCT	Canada		2697189		19-Feb-2010		DOSING REGIMEN
08.2027		PCT	Canada		683067.5	EP 2 197 448	12-Sep-2008		DOSING REGIMEN
08.2027		PCT	Japan		2010-525050		11-Mar-2010		DOSING REGIMEN
08.2027		ORD	PCT		PCT/AUS2008/076189	WO/2009/035267 A1	12-Sep-2008		DOSING REGIMEN
08.2030		PCT	Australia		200822020		30-Jul-2010		STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
08.2030		ORD	Taiwan		98105648	200840552	03-Mar-2009	03-Mar-2029	STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
08.2034		ORD	PCT		PCT/AUS2010/036127	WO/2010/138539	26-May-2010	25-May-2014	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
08.2034		ORD	Taiwan		98116806		28-May-2010	28-May-2030	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
EMT 04 A		ORD	USA	5342406	07809.196		16-Dec-1991	16-Dec-2011	DEVICE & METHOD FOR DISPENSING A LIQUID PARTICULARLY USEFUL FOR DELIVERING MEDICAMENTS AT A PREDETERMINED RATE

Asset Transfer Agreement (EPH to EDI Pharma Holdings) - 2 August 2017
 Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
EMT 25		ORD	USA	5312408	09/331,848		07-Sep-1999	07-Sep-2019	DEVICE FOR GENERATING A PULSATILE FLUID DRUG FLOW
EMT 54		DES	USA	D454,194 S	29/135,976		23-Jan-2001	05-Mar-2016	DRUG RECONSTITUTION AND INJECTION DEVICE
EMT BD 13		ORD	USA	11695	29/135,976		17-Nov-1994	17-Nov-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13		PCT	Israel	11695	11695		17-Nov-1994	17-Nov-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13		ORD	New Zealand	276495	276495		18-Jan-1994	18-Jan-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13	2	COM	USA	5987501	08/183,482		19-Aug-1996	07-Dec-2016	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 18	2	EPC	Ireland	EP 0 850 076	99931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 18		EPC	Luxembourg	EP 0 850 076	99931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 18		EPC	Monaco	EP 0 850 076	99931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 18		EPC	United Kingdom	EP 0 850 076	99931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 18		ORD	USA	5814020	08/708,230		06-Sep-1996	06-Sep-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 22	2	ORD	USA	5658001	08/763,311		10-Dec-1996	10-Dec-2016	CARTRIDGE-BASED DRUG DELIVERY DEVICE
EMT 23			United States	US 5871125	08/697,992		04-Jun-1997	04-Jun-2017	Liquid delivery packaging device
EMT BD 24		PCT	Australia	723947	3197297		04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		PCT	EP	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	France	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	Germany	99718912.0	99718912	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		ORD	Ireland	60772	950427		10-Jun-1996	10-Jun-2016	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	Italy	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	United Kingdom	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		ORD	USA	5261272	09/292,176		01-Jun-1999	04-Jun-2017	NEEDLE AND METHOD FOR DELIVERY OF FLUIDS
EMT BD 24	3	COM	USA	8348095	09/778,332		06-Feb-2001	04-Jun-2017	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 28	2	PCT	Japan		2001-885867		23-May-2001	23-May-2021	IMPROVED FILLING SYSTEM
EMT BD 28	2	ORD	USA	6630900	09/577,033		23-May-2000	05-May-2018	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 28	3	ORD	USA	6186982	09/072,875		05-May-1995	05-May-2019	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 32		ORD	Taiwan	NI-111528	87109549	880046	18-Jun-1998	18-Jun-2018	METHODS OF CALIBRATING AND TESTING A SENSOR FOR IN VIVO MEASUREMENT OF AN ANALYTE AND DEVICES FOR USE IN SUCH METHODS
EMT BD 32		ORD	USA	6275717	08/102,840		23-Jun-1998	23-Jun-2018	METHODS OF CALIBRATING AND TESTING A SENSOR FOR IN VIVO MEASUREMENT OF AN ANALYTE AND DEVICES FOR USE IN SUCH METHODS
EMT BD 33	3	ORD	USA	6000548	08/102,841		23-Jun-1998	23-Jun-2018	DRUG DELIVERY KIT AND METHOD OF PACKAGING THE SAME
EMT BD 36		PCT	Japan	4348011	2000-548337		18-May-1999	18-May-2019	ADHESIVE SYSTEM FOR ATTACHING MEDICAL DEVICES TO A SURFACE
EMT BD 38		EPC	France	EP 1 064 035	99912015.7	EP 1 064 035	22-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38		EPC	Germany	69913111.1	98913015.7	EP 1 064 035	22-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38		PCT	Japan	4425465	2000-537500	2002507459	24-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38	3	ORD	USA	6086958	08/278,464		23-Mar-1999	23-Mar-2019	IMPROVED DRUG DELIVERY DEVICE

Asset Transfer Agreement (EPH to EDI Pharma Holdings) - 2 August 2011
 Schedule 2. Patents

EDI Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
EMT BD 38	3	INV	USA	7384413	10461040	US 2003-0236499 A1	13-Jun-2003	23-Mar-2019	DEVICE FOR MEASURING VOLUME OF DRUG
EMT BD 38	4	INV	USA		12/121,545		15-May-2006	29-Mar-2019	IMPROVED DRUG DELIVERY DEVICE
EMT BD 38			USA		13/184,473		15-Jul-2011		IMPROVED DRUG DELIVERY DEVICE
EMT BD 38			USA		13/184,473		15-Jul-2011		IMPROVED DRUG DELIVERY DEVICE
EMT BD 45		PCT	Japan	4659627	2000-575564		08-Oct-1999	06-Oct-2019	A METHOD AND DEVICE FOR ENTRAPPING GAS WITHIN A LIQUID DRUG CONTAINER
EMT BD 46		ORD	USA	7520954	08/883,025		17-Jun-2001	03-Oct-2023	NEEDLE DEVICE AND METHOD AND OPERATION THEREOF
EMT BD 50		PCT	Japan		2001-677072		12-Apr-2001	12-Apr-2021	IMPROVED ELECTROLYTIC CELL